A review of the health effects of stimulant drinks. by unknown
A Review of the Health Effects
of Stimulant Drinks
Final Report

Foreword i
Acknowledgements ii
Members of the Stimulant Drinks Committee iii
Executive Summary iv
1. Introduction 1
1.1 Background to the Committee 1
1.2 Terms of reference of the Committee 1
1.3 Scope of work of the Committee 1
2. Stimulant Drinks – Definition and Regulatory Framework 3
2.1 Definition of stimulant drinks 3
2.2 Range of stimulant drink products 3
2.3 The growth of the stimulant drink market 4
2.4 Regulations and legislation pertaining to stimulant drinks 4
2.4.1 Ireland and other EU Member States 4
2.4.2 Other international legislation 5
2.5 Summary 6
3. Individual Ingredients of Stimulant Drinks 7
3.1 Introduction 7
3.2 Caffeine 7
3.2.1 Introduction 7
3.2.2 Sources of caffeine and caffeine content 7
3.2.3 Caffeine metabolism 11
3.2.4 Potential effects of caffeine 11
3.2.4.1 Behavioural effects of acute and chronic exposure to caffeine 11
3.2.4.2 Cardiovascular effects of caffeine 11
3.2.4.3 Caffeine and diuresis 12
3.2.5 Groups for special consideration 13
3.2.5.1 Caffeine and pregnancy 13
3.2.5.2 Caffeine and children 13
3.2.5.3 Caffeine and individuals with caffeine sensitivity 14
3.2.6 Drug interactions and caffeine 14
3.2.6.1 Caffeine and alcohol 14
3.2.6.2 Caffeine consumption and tobacco 14
3.2.6.3 Caffeine and analgesics and other prescription medicines 14
3.2.6.4 Caffeine and recreational drugs 14
3.2.7 Caffeine – summary 15
3.3 Guarana 15
3.3.1 Introduction 15
3.3.2 Sources of guarana 15
3.3.3 Potential effects of guarana 16
3.3.4 Guarana – summary 17
A Review of the Health Effects of Stimulant Drinks
Contents
3.4 Taurine 17
3.4.1 Introduction 17
3.4.2 Sources of taurine 17
3.4.3 Potential effects of taurine 17
3.4.4 Taurine – summary 19
3.5 Glucuronolactone 19
3.5.1 Introduction 19
3.5.2 Sources of glucuronolactone 19
3.5.3 Potential effects of glucuronolactone 20
3.5.4 Glucuronolactone – summary 20
4. Effects of the Combined Ingredients of Stimulant Drinks 23
4.1 Introduction 23
4.2 Physiological effects of stimulant drinks under the circumstances in which they are consumed 23
4.2.1 Sport 23
4.2.1.1 Caffeine during exercise 23
4.2.1.2 Carbohydrate during exercise 24
4.2.1.3 Interaction between caffeine and carbohydrate upon exercise performance 24
4.2.1.4 Stimulant drinks and exercise 24
4.2.2 Social context 25
4.2.2.1 Alcohol 25
4.2.2.2 Recreational drugs 25
4.3 Behavioural/performance effects of stimulant drinks 26
4.4 Acute physiological effects of stimulant drinks 26
4.5 Summary 27
5. Consumer Perceptions 29
5.1 Introduction 29
5.2 Methodology 29
5.3 Results 29
5.3.1 Concerns of parents of consumers 29
5.3.2 Concerns of young adult consumers, 18 – 24 years 29
5.3.3 Concerns of young consumers 30
5.4 Summary 30
6. Studies of Consumption Levels and of Behaviour and Attitudes to Stimulant Drinks 33
6.1 Introduction 33
6.2 Background 33
6.2.1 International studies 33
6.2.2 Consumption on the island of Ireland 33
6.3 Survey of the consumption patterns of stimulant drinks on the island of Ireland 33
6.3.1 Methodology 34
6.3.2 Results 34
6.3.2.1 Overall demographics of survey 34
6.3.2.2 Frequency of drinking 34
6.3.2.3 Prevalence of regular consumers of stimulant drinks by sex, age and social class 35
A Review of the Health Effects of Stimulant Drinks
6.3.2.4 When respondents started to drink stimulant drinks 35
6.3.2.5 Settings in which stimulant drinks were consumed 36
6.3.2.6 Consumption levels of stimulant drinks 38
6.3.2.7 Consumption of stimulant drinks with alcohol 39
6.3.2.8 Attitudes and behaviour towards stimulant drinks 39
6.4 Summary 41
7. Marketing of Stimulant Drinks 43
7.1 Introduction 43
7.2 Stimulant drinks in Ireland – summary of a marketing review 43
7.2.1 The stimulant drink market on the island of Ireland 43
7.2.2 Distribution of Red Bull on the island of Ireland 44
7.2.3 Marketing strategies 44
7.2.3.1 Advertising 44
7.2.3.2 Sampling 44
7.2.3.3 Sponsorship 44
7.3 Regulation of the advertising of stimulant drinks 45
7.3.1 Advertising regulation in the Republic of Ireland 45
7.3.2 Advertising regulation in the United Kingdom 45
7.4 Summary 46
8. Recommendations 49
8.1 Introduction 49
8.2 Labelling 49
8.3 Groups for special consideration 49
8.4 Circumstances under which stimulant drinks are consumed 50
8.5 Marketing 50
8.6 Further research 50
Appendices 51
Appendix I Stimulant drink survey questionnaire 51
Appendix II Table I: Demographics of respondents in the Republic of Ireland 55
Appendix III Table II: Demographics of respondents in Northern Ireland 55
Glossary 57
References 59
A Review of the Health Effects of Stimulant Drinks
Tables
Table 2.1 Stimulant drink products typically available on the island of Ireland 4
Table 3.1 The caffeine content of some common beverages and foods 8
Table 3.2 Putative physiological functions of taurine 16
Table 3.3 Summary of taurine toxicity studies in humans 17
Table 6.1 Whether ‘ever’ respondents had ever consumed a number of specified drinks 29
Table 6.2 Whether ‘ever’ respondents regularly consumed a number of specified drinks 29
Table 6.3 Distribution of regular consumers of stimulant drinks by age, sex and social class 30
Table 6.4 Times at which regular drinkers consumed stimulant drinks 31
Table 6.5 Regular stimulant drink consumers (18 – 35 years) who reported consuming 
stimulant drinks with alcohol 33
Table 6.6 Regular stimulant drink consumers (18 – 35 years), by sex, who reported consuming 
stimulant drinks with alcohol 33
Table 6.7 Respondents claiming attribute for each category 34
Table 6.8 Agreement with statements (all consumers) 34
Table I Demographics of respondents in the Republic of Ireland 43
Table II Demographics of respondents in Northern Ireland 43
Figures
Figure 6.1 When ‘ever’ consumers began drinking stimulant drinks 30
Figure 6.2 When ‘regular’ consumers began drinking stimulant drinks 30
Figure 6.3 Settings in which stimulant drinks were regularly consumed 31
Figure 6.4 The average number of cans of stimulant drinks consumed within each age group 
by ‘ever’ consumers 32
Figure 6.5 The average number of cans of stimulant drinks consumed by male and female ‘ever’ 
consumers 32
A Review of the Health Effects of Stimulant Drinks
Over the last decade, stimulant drinks have developed a considerable share of the global soft drinks market.
Legislation controlling their sale and marketing and scientific research into their ingredients lags behind the
development of these ‘functional’ beverages. 
Some countries, within the European Union (EU), and also Australia and New Zealand have had concerns
regarding the potential health effects of stimulant drinks. There are a number of countries where these products
are not sold owing to statutory limits on the concentrations of their ingredients, while others stipulate for
additional labelling of the products.
At the request of the Minister of State at the Department of Health and Children in the Republic of Ireland, the
Food Safety Promotion Board (FSPB) convened an expert Committee to review the health effects of stimulant
drinks. This report is the outcome of the Committee’s work. 
The lack of scientific research into some of the ingredients found in stimulant drinks, and the unrecorded health
effects of the combined ingredients, has made this task a difficult one. However, this report should prove to be
valuable. It aims to raise awareness regarding the health effects of these products for particular subsections of the
population on the island of Ireland, and it sets out recommendations to address the gaps in the current
knowledge. It is hoped that the concerns highlighted in this report will be addressed by policy makers and
researchers, and will ultimately influence the behaviour of the population.
Professor J.J. Strain
Chair
Stimulant Drinks Committee
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Members of the Stimulant Drinks Committee
Background
The Food Safety Promotion Board, following a
request from the Minister of State at the Department
of Health and Children, Dr. Tom Moffatt T.D.,
established the Stimulant Drinks Committee
(consisting of external experts) to carry out research
into the health effects of stimulant drinks. 
The task and terms of reference for the group were:
• to review the potential health effects on the
population of Ireland from the consumption of
stimulant drinks 
• to assess the knowledge gaps 
• to consider the need for any action to protect
public health. 
In addition to this, the Committee agreed to take
into account claims made in relation to the
advertising and marketing of stimulant drinks, as
well as the legislation and regulations pertaining to
these products in other countries. The Committee
reviewed the available information regarding the
main ingredients of stimulant drinks and relevant
research studies into the health effects. However, it
was limited by the lack of information and adequate
risk assessment data pertaining to stimulant drinks.
The Definition of a Stimulant Drink 
There is no agreed definition in the regulatory
framework for the products referred to as ‘energy’ or
‘stimulant‘ drinks. For the purpose of this report, the
term ‘stimulant drinks’ was adopted and these drinks
are defined as ‘beverages, which typically contain
caffeine, taurine and vitamin(s), and may contain an
energy source (e.g. carbohydrate), and/or other
substance(s), marketed for the specific purpose of
providing real or perceived enhanced physiological
and/or performance effects’.
Availability
There are several stimulant drink products available
to the consumer on the island of Ireland. These
products all contain caffeine at a typical
concentration of 80 mg per 250 ml can, with the
majority of drinks containing taurine and some
containing glucuronolactone. The report considers
these ingredients in detail.
Sales of stimulant drinks grew rapidly following their
introduction on to the market on the island
(1999/2000). However, sales of stimulant drinks
appear to have slowed thereafter. 
Legislation
Although there is no legislation relating specifically to
stimulant drinks in Ireland or the United Kingdom (UK)
these beverages are governed by the existing food
legislation. In the UK the Food Advisory Committee
(FAC) of the Ministry of Agriculture, Food and Fisheries
(MAFF) recommended in 1999 that products, such as
stimulant drinks, containing caffeine at concentrations
greater than 125 milligram per litre (mg.l-1) should carry
a clear statement on the label regarding the levels of
caffeine present and an indication that they are
unsuitable for children or individuals sensitive to
caffeine. In February 2002, EU Member States agreed
changes to the labelling regulations. These changes will
require drinks with caffeine contents greater than 150
mg.l-1 to be labelled ‘high caffeine content’ and the
amount of caffeine present must be given. The new
rules must come into effect by July 1st 2004.
Executive Summary
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Consumption
A survey of the consumption of stimulant drinks in a
representative sample of 11 – 35 year olds in the
Republic of Ireland (total sample number (n) = 625)
and in Northern Ireland (n = 635) was commissioned
by the FSPB in 2001. This age group was chosen as it
was thought to be most akin to the young
population who use these products. Results of the
survey showed the following:
• 51% (Northern Ireland) and 37% (Republic of
Ireland) of individuals in this age group have
consumed stimulant drinks at least once
• 10% those who had ever consumed stimulant
drinks were regular consumers with the highest
prevalence among males aged 19 - 24 years
• The most common location of consumption was
‘pubs/clubs’, but stimulant drinks were also
consumed ‘with friends’, ‘at home’, ‘before or
after sport’ and occasionally in association with
‘study/work’. Very few reported drinking
stimulant drinks in association with driving
• Stimulant drinks were frequently consumed with
alcohol, particularly vodka
• The weekly consumption of stimulant drinks was
approximately three cans (each can containing 250
ml) among ‘ever’ consumers, rising to about eight
cans among the highest ‘ever’ consumers
• Similarly, in a single session the average amount
of stimulant drinks consumed was approximately
three cans and among the highest consumers this
rose to eight cans. This would suggest that the
weekly consumption of stimulant drinks takes
place in a single session.
Stimulant drink consumers reported strong or
moderate agreement for consumption of stimulant
drinks with the following reasons:
“to perk themselves up when tired”
“on big nights out”
“to perk themselves up if they have too 
much to drink”
“with alcohol to enable them to drink more 
in an evening”
Qualitative research was carried out to assess the
concerns of the public regarding the consumption 
of stimulant drinks. Results of the research
demonstrated that the main concerns vis à vis
stimulant drinks were its consumption with alcohol,
the perceived ‘high’ caffeine content and the sense
of ambiguity and uncertainty regarding the other
ingredients. Parents were more actively concerned
than consumers, the latter acknowledging the risks
but continuing to drink the product. 
Possible Adverse Health Effects 
of Stimulant Drink Ingredients
Caffeine
Caffeine is one of the main ingredients of stimulant
drinks and it is also present in tea, coffee and other
beverages and foods. The average total intake of
caffeine in the Republic of Ireland and the UK is
estimated to be 214 and 278 mg per person per day,
respectively. Data from the consumption survey, based
on weekly intake, indicates that among stimulant
drink consumers, the average daily caffeine intake
from stimulant drinks alone would be approximately
35 mg, rising to about 90 mg among the highest
consumers. This does not appear excessive, however,
when the consumption of stimulant drinks in a single
session was investigated, the average caffeine
consumed was approximately 240 mg (3 cans), rising
to about 640 mg (8 cans) among the highest
consumers. Such large intake levels among the
highest consumers are a cause of concern, particularly
in relation to the known potential acute health effects
of caffeine such as tachycardia, increases in blood
pressure and dehydration, as well as behavioural and
cognitive effects. The health effects of chronic or
habitual caffeine consumption remain uncertain.
Although no data is available on stimulant drink
consumption during pregnancy, the relatively high
caffeine content requires that these beverages be
Executive Summary
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taken into consideration with regard to advice on
caffeine intake during pregnancy. On the basis of a
possible association of high caffeine intake (in excess
of 300 mg per day) with low birth weight and
spontaneous abortion, both the FSAI and the FSA UK
recommend that pregnant women should limit their
daily intake of caffeine to 300 mg (equivalent to
about four average cups of coffee, six average
cups of tea, eight cans of regular soft drink or four
cans of stimulant drinks).
There is limited data available on stimulant drink
intake by children under 11 years, the relatively high
caffeine content of stimulant drinks requires that
these beverages be taken into consideration with
regard to advice on caffeine intake by children. In
experimental studies in which single doses of
caffeine up to 10 milligram per kilogram (mg.kg-1)
body mass were given to children, either no effect or
small, inconsistent effects were noted on mood,
behavioural, cognitive and motor functions. Some of
the effects may be interpreted as beneficial.
However, some studies have indicated that a dose of
5 mg.kg-1 body mass (equivalent to 150 mg caffeine
per day, 4 – 5 cans of a cola drink, for a 10 year-old,
30 kg child) increased arousal, irritability, nervousness
or anxiety in some children, particularly if they were
normally low consumers of caffeine.
Information on the possible interactions in humans
of caffeine with other constituents of stimulant
drinks, such as taurine, is very limited. These
interactions warrant further investigation.
Guarana
Guarana (Paullinia cupana) is a native South American
plant containing guaranine, a substance chemically
similar to caffeine with comparable stimulant effects.
Guarana is often added to stimulant drinks, either in
combination with caffeine or on its own.
The stimulant effect of guarana is related to its caffeine
content; one gram of guarana contains as much
caffeine (40 mg) as a medium strength cup of coffee.
While the precise source and nature of the stimulant
activity of guarana is not well understood, it has been
reported that guarana exerts a more prolonged effect
than an equivalent amount of caffeine.
There are reports in the literature of toxicosis
associated with guarana in experimental animals.
However, the information is limited. The Food and
Drinks Administration (FDA) in the USA currently
prohibits the use of guarana in food and drinks
while awaiting further clarification on its safety.
The FSA UK and the European Commission (EC)
are also reviewing the use of guarana in foodstuffs.
Taurine
The data on stimulant drink intake among stimulant
drink consumers indicate that average daily taurine
intake from stimulant drinks was approximately 0.4g,
increasing to about 1g among the highest
consumers. The most taurine consumed from
stimulant drinks in a single session was averaged at
approximately 3g, rising to about 8g by the highest
consumers. Stimulant drink intake at the maximum
level of intake provides taurine far in excess of that
from other foods or beverages in the diet. While
limited, the data available indicate no evidence of
adverse effects of taurine at such intakes and in a
recent report the EU Scientific Committee for Food
(SCF) was unable to conclude that the ‘safety-in-use’
of taurine in the concentration range reported for
stimulant drinks has been adequately established.
Further research into this ingredient is required.
Glucuronolactone
The data from the consumption survey indicate that
average daily glucuronolactone intake from stimulant
drinks was approximately 0.25g, rising to about 0.7g
among the highest consumers. The most
glucuronolactone consumed from stimulant drinks in
a single session was averaged at approximately 1.8g,
rising to about 4.8g among the highest consumers.
These maximum levels of intake provide more
glucuronolactone than would otherwise be achieved
through other foods or beverages in the diet. There
is very little information available for risk assessment
of glucuronolactone at such intakes. While there is
no indication from the available data that there is
any risk to health from consumption of high
amounts of glucuronolactone, these data are limited.
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Similar to taurine, the EU SCF was unable to
conclude that the ‘safety-in-use’ of glucuronolactone
in the concentration range reported for stimulant
drinks has been adequately established. 
Stimulant Drink Consumption in
Association with Sport and Exercise 
Stimulant drinks are sometimes promoted for use 
in sport. Caffeine has been shown to enhance
performance in some sporting activities and for this
reason, caffeine intake in sport is regulated by the
International Olympic Committee (IOC). It is not clear
whether other ingredients of stimulant drinks
(taurine and glucuronolactone) have effects on
performance during sport and exercise or whether
these ingredients potentiate or attenuate the actions
of caffeine when used in sport. 
Stimulant drinks are not suitable for use as rehydration
drinks in association with sport or exercise. Unlike
isotonic sports drinks, stimulant drinks do not meet the
compositional requirements (with respect to osmolarity
and concentrations of carbohydrate and electrolytes)
recommended for such beverages to ensure optimum
hydration. Little is known about the possible adverse
effects on exercise performance and fluid balance
during sport and exercise occurring from the
interaction of the principal ingredients contained in
stimulant drinks. Further research is necessary.
Stimulant Drink Consumption in
Association with Alcohol 
The consumption survey showed that stimulant
drinks were frequently consumed with alcohol,
particularly vodka. There is little information on 
the possible interactions between alcohol and the
ingredients of stimulant drinks, such as caffeine
and taurine, when consumed at the relatively high
levels observed with some consumers. This
warrants investigation in humans, particularly
under conditions of exercise and consequent
dehydration through sweating. 
Furthermore, the survey also provided evidence that
some individuals consume stimulant drinks to ‘perk’
themselves up if they had too much to drink and with
alcohol to enable them ‘to drink more in an evening’.
Such use of stimulant drinks may contribute to
increased alcohol consumption. While the
manufacturers of stimulant drink assert that they 
do not encourage the consumption of the drinks with
alcohol, some of the promotional materials and
information supplied by the manufacturers are
ambiguous with regard to this and appear to ostensibly
promote the use of stimulant drinks with alcohol.
Marketing and Claims
The FSPB commissioned an assessment of the
marketing of stimulant drinks in Ireland in
March/April 2001. Market analysis indicates that the
sales of stimulant drinks on the island of Ireland have
peaked, and in 2001 sales were running at
approximately 20% below those of 2000. Recent
analysis suggests that other more ‘trendy’ products
on the market are replacing stimulant drinks with
alcohol. However, there remains a strong and loyal
consumer base of stimulant drinks and there are
indications that many consumers continue to
consume these drinks with alcohol. 
The analysis of the marketing activity of stimulant
drinks highlights a number of areas for concern
including:
• Some of the verbal messages being given by the
sampling staff may be over-emphasising the
benefits of the product 
• Some promotional brochures encourage people
to drink stimulant drinks rather than to sleep
• In general, no recommended upper consumption
limits are provided (other than for athletes
concerned with sports regulations on permissible
levels of caffeine).
Executive Summary
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Recommendations
In reviewing the adverse health effects of stimulant
drinks, the Committee was constrained by the
limited amount of comprehensive information, 
risk assessment data and peer reviewed scientific
research in this area. In light of this limited
information and in order to protect public health,
the Committee has adopted a precautionary
approach to its review and makes the following
recommendations:
Labelling
The Committee welcomes the changes to the
labelling regulations requiring drink products with
caffeine contents greater than 150 mg.l-1 to be
labelled ‘high caffeine content’ and the amount of
caffeine present be given. This should be
implemented as soon as is practicable. 
The Committee also recommends that stimulant drinks
should be labelled with an indication that they are
unsuitable for children (under 16 years of age),
pregnant women and individuals sensitive to caffeine.
Groups for special consideration
In the context of advice to pregnant women to limit
caffeine intake owing to the possible adverse effects
of high caffeine intake on pregnancy outcome,
stimulant drinks should be classified with other
beverages of high caffeine content.
Consumption of stimulant drinks by children under
16 years should be discouraged on the basis of
possible transient behavioural effects of high caffeine
intake, such as increased arousal, irritability,
nervousness or anxiety.
Circumstances under which stimulant 
drinks are consumed
Consumers should be advised that caution be
exercised in the consumption of stimulant drinks
with alcohol and the products should carry a clear
statement on the label to this effect.
It is recommended that stimulant drinks not be
consumed in association with sport and exercise as a
thirst quencher and that the products should carry a
clear statement on the label that they are unsuitable
rehydration agents for use in sport and during exercise.
Marketing
The Committee has a number of concerns about the
marketing and promotion of stimulant drinks including:
• misleading claims
• suggestion that stimulant drinks reduce the
requirement for sleep 
• lack of recommended upper consumption limits
• ambiguous information on the consumption of
stimulant drinks with alcohol 
• promotion of stimulant drinks consumption in
association with sport. 
It is recommended that the industry regulators and
relevant authorities address such practices.
Further research
The Committee recognises that in order to undertake
a full risk assessment of the ingredients of stimulant
drinks and their interactions, extensive research
would need to be conducted. Such research would
require toxicological investigations that would best
be carried out at a concerted international level.
It is recommended that further research be carried
out to:
• monitor patterns of stimulant drink consumption
• establish an upper safe level for daily intake of
glucuronolactone and taurine in humans
• investigate possible adverse effects of interactions
between stimulant drink ingredients such as
caffeine and taurine and between such
ingredients and alcohol, particularly under
conditions of exercise and consequent
dehydration through sweating.
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‘Large caffeine intake
levels are a cause of
concern, particularly
in relation to known 
potential acute health
effects such as
tachycardia, increases
in blood pressure and
dehydration, as well 
as behavioural and
cognitive effects.’
‘There is no agreed
definition in
the regulatory
framework for the
products referred
to as ‘energy’ or
‘stimulant’ drinks’.
1.1 Background to the Committee
On November 14th 2000, an inquest was held into the
death of an 18 year old, male student. The inquest
heard evidence that the student collapsed and died
during an interval at a basketball tournament in which
he was participating. Following autopsy the coroner
concluded that the young man had died from sudden
unexplained adult death syndrome, possibly resulting
from cardiac dysrhythmia. In its verdict, the jury
concluded that death was as a result of this rare
syndrome. However, on the basis of evidence from
witnesses who described having seen the young man
drink up to three cans of a stimulant drink, during the
tournament, the jury added a rider to the verdict that
immediate research be carried out into the safety of
stimulant drinks available on the Irish market.
Following the inquest and the jury’s
recommendations, the Minister of State at the
Department of Health and Children, Dr. Tom Moffat
T.D., requested that the Food Safety Promotion
Board commission independent scientific research
into the health effects of stimulant drinks.
It is on this basis that the FSPB established the
Stimulant Drinks Committee comprising medical and
scientific experts to review the issue. This report is
the outcome of the Committee’s deliberations.
1.2 Terms of Reference of 
the Committee
In consultation with the Department of Health and
Children, the Committee developed the following
terms of reference:
• To review the potential health effects on the
population of Ireland from the consumption of
stimulant drinks
• To assess the knowledge gaps
• To consider the need for any action to protect 
public health.
1.3 Scope of Work of the Committee
The Committee agreed that the broad areas of work
should be to:
i) review the research on the health effects of
stimulant drinks
ii) ascertain consumption patterns of stimulant
drinks within population groups 
iii) advise on the need for research and identify
priority areas
iv) advise on the need for action, if required, 
to protect public health. 
In addition to the above, the Committee also agreed
to take into account, claims made in relation to the
advertising and marketing of stimulant drinks, as
well as the legislation and regulations pertaining to
these products in other countries.
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Introduction
2‘There is currently
no specific legislation
governing stimulant 
drinks within the EU, 
nor is there a general
consensus with
regard to the
permissible
concentrations of
the individual
ingredients’.
2.1 Definition of Stimulant Drinks
Stimulant drinks are a relatively recent introduction
to the global soft drink market. These drinks contain
a caffeine source and a carbohydrate source such as
glucose or sucrose. They may also contain other
ingredients including glucuronolactone, taurine and
some of the B vitamins. 
The drinks are generally packed in visually attractive
slimline cans and positioned at the upper end of the
soft drink market. Stimulant drinks belong to a new
class of food known as ‘functional foods’. These
foods purport to target and favourably affect
particular functions of the body.
While falling into the non-alcoholic beverage
category, there is no agreed definition applicable for
these products in the regulatory framework. The
Committee considered the terms ‘energy drinks’ and
‘formulated caffeinated beverages’ but selected the
term ‘stimulant drinks’ to describe the products
under examination. The Committee considered that
the term ‘stimulant drinks’ more precisely reflected
the perceived stimulant effect of the drinks, which
was the focus of the review. Moreover, while
caffeine may play a significant role in the functional
properties of stimulant drinks, it is possible that the
other ingredients present, such as taurine and
glucuronolactone, may also contribute to the overall
effect. For the purposes of this report the
Committee, therefore, agreed on the following
definition of stimulant drinks: 
Beverages, which typically contain caffeine, taurine
and vitamin(s) and may contain an energy source
(e.g. carbohydrate) and/or other substance(s),
marketed for the specific purpose of providing real
or perceived enhanced physiological and/or
performance effects. 
It is important to differentiate between stimulant
drinks and the drinks referred to as ‘sports’ or
‘isotonic’ drinks as these products have distinctly
differing functions and composition. 
Sports drinks provide two major functions:
i) maintenance of fluid balance and electrolyte
concentration
ii) provision of energy for use either during exercise
or in recovery from exercise.
Sports drinks, as so described, do not normally
contain the principal ingredients of stimulant drinks,
i.e. caffeine, taurine and glucuronolactone and
hence do not fulfil the criteria of the definition of a
stimulant drink as outlined above. Furthermore, it
should also be noted that the IOC currently considers
caffeine to be a stimulant which can result in athlete
disqualification at urinary concentrations in excess of
12 milligram per litre (mg.l -1) of urine. 
2.2 Range of Stimulant Drink Products
There is a wide range of stimulant drink products
available to the consumer on the island of Ireland.
These products all contain caffeine at a typical
concentration of 80 mg per 250 ml can (Table 2.1),
and the majority of drinks also contain taurine and
carbohydrate, while some contain glucuronolactone.
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Stimulant drinks – Definition and Regulatory Framework
While all these products have at some time or another
been available on the market on the island, the
product ‘Red Bull’, manufactured by Red Bull GmbH,
dominates the market with an 87% share (2, 3).
2.3 The Growth of the Stimulant 
Drink Market
Since the original launch of stimulant drinks in 1987
in Austria, there has been enormous growth in their
sales worldwide. Market statistics for the Republic of
Ireland in 2000 indicate that stimulant drinks
represented less than 2% of the total soft drink
market but that the category was growing rapidly (2).
Sales of ‘Red Bull’ on the island reached 1.43 million
cases (8.58 million litre) in 2000 with approximately
70% of sales occurring in the Republic of Ireland and
30% in Northern Ireland. This represents a two-fold
increase in sales on the previous two years (3).
However, market analysis suggests that this trend has
since slowed (Chapter 7).
2.4 Regulations and Legislation
Pertaining to Stimulant Drinks
2.4.1 Ireland and other EU Member States 
Currently there is no EU legislation pertaining
specifically to stimulant drinks. Like other soft drinks,
stimulant drinks are subject to the general EU labelling
directives and applicable horizontal legislation.
While to date there is no specific legislation, a
number of EU Member States have introduced their
own domestic legislation governing stimulant drinks
or ingredients therein, particularly caffeine. Certain
Member States, including France and Denmark, have
set statutory upper levels of caffeine in soft drinks of
150 mg.l-1 and stimulant drinks are currently not sold
within these jurisdictions.
As well as caffeine, the French authorities also have
concerns regarding the health effects of some of
the other ingredients of stimulant drinks namely
taurine and glucuronolactone (4). In February
2001, the French food safety agency (Agence
Française de Sécurité Sanitaire des Aliments,
AFSSA) published its consultation findings on a
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Caffeine Taurine Glucuronolactone Carbohydrate
Absolute Bull 80 1000 600 28.3
American Bull 80 * ** 28.0
Dynamite 80 1000 ** 31.3
Indigo Extra 63~ 1000 ** 35.0
Jolt Cola ± ** ** *
Lipovitan B3 50 1000 ** 27.0
Red Bull 80 1000 600 28.3
Shark 75~ 1000 * 37.5
Spiked Silver 80~ 1000 600 33.8
V 80~ 500§ 62.5§ 28.0
Brand Name Concentration of ingredient as shown on label
mg per 250 ml can
* Not given
** Not listed in the ingredients listing
~ Includes caffeine in the form of guarana
± No indication of actual concentration given on label but states that the level of caffeine present 
is ‘equivalent to one cup of coffee’ (see Table 3.1)
§ Actual concentrations not given in ingredients listing (1)
Table 2.1 Stimulant drink products typically available on the island of Ireland and their ingredients
toxicological study of a stimulant drink product. 
In its report the AFSSA stated that in the case of
taurine and glucuronolactone: “it could not
guarantee with certainty that the substances
contained within the product did not present any
health risk”. The report further added: “it is
recommended to proceed with further in-depth
research to pinpoint a daily maximum absorption
threshold for taurine and glucuro-∂-lactone
[glucuronolactone]”.
Following a review of the toxicological study carried
out on behalf of the manufacturer, the AFSSA
concluded that authorisation for the use of the drink
was:“not acceptable, as their safety in the
concentrations promoted by the petitioner has not
been demonstrated”. 
Up to 1996, Italy also had a statutory permitted
level of caffeine of 150 mg.l -1 (5). The EU initiated
a procedure of infringement against Italy for
creating a barrier to trade within the EU market.
The Italian Health Superior Council subsequently
conducted a study on the health effects of the
high concentrations of caffeine and taurine.
Following the completion of the study, the Council
suggested that if the products containing caffeine
were to be sold within Italy, that additional
labelling was to be included on the product
container to the effect: 
• that children, pregnant women and caffeine
sensitive individuals should avoid the products
• that moderate consumption of the products be
advised with the contemporary consumption of
caffeine from other sources
• that claims on the beneficial effects of these
beverages which cannot be adequately documented
should not be included on the label
• that the contemporary exposure to alcohol and
tobacco with the drinks should be avoided.
In light of the review of the amendment to the
labelling directive 2000/13/EC, the EU has stayed
proceedings on this case. 
In February 1999, the UK FAC of MAFF recommended
that a statutory maximum limit of 125 mg.l -1 be set
for caffeine in soft drinks and that a voluntary
statement outlining the unsuitability of caffeine for
children and those sensitive to caffeine be included
on the label of caffeine-containing products (6).
Following the publication of the 1999 report from
the EU SCF on ‘energy’ drinks (7), the initial
statement was subsequently reconsidered and a new
statement issued indicating that in soft drinks, more
likely to be consumed in large quantities by children,
caffeine concentrations should not exceed 125 mg.l-1.
It was recommended that products, such as stimulant
drinks, containing caffeine at concentrations greater
than 125 mg.l -1, should carry a clear statement on
the label indicating the levels of caffeine present and
a statement advising their unsuitability for young
children or those sensitive to caffeine (8). 
The EU Standing Committee for Foodstuffs has
considered an amendment to the labelling directive
2000/13/EC (9). Member States agreed in February
2002 to an amendment requiring specific labelling
indicating the presence of caffeine and quinine in
foods when used as a flavouring or ingredient.
Products that contain levels of more than 150
mg.kg -1 (or mg.l -1) caffeine will in the future be
labelled ‘high caffeine content’ and the exact
amount present indicated on the label. The new
rules must come into effect by July 2004.
2.4.2 Other international legislation
The issue of energy (stimulant) drinks was raised at
the Codex Committee on Nutrition and Foods for
Special Dietary Uses (CCFSDU) in June 2000 (10). 
At this session there were inconclusive discussions
over whether stimulant drinks should be classed as
soft drinks or require specific classification. There was
also a call for further definition of the term ‘high
energy’. In November 2001, the CCFSDU further
discussed the issue of stimulant drinks. It was
decided at this session that no standard for energy
(stimulant drinks) or sports drinks was necessary (11). 
In order to facilitate international trade by removing
the existing regulatory inequalities between Australia
and New Zealand in relation to formulated
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caffeinated beverages (stimulant drinks), the
Australian New Zealand Food Authority (ANZFA)
commissioned a working group in 2000 to
investigate the safety aspects of these products. 
In the ANZFA ‘Full Assessment Report and Regulation
Impact Assessment’ published in November 2000
(12), the group recommended that stimulant drink
products should be labelled with the following
information:
• an advisory statement regarding the presence 
of caffeine
• an advisory statement regarding the suitability 
of the product to particular segments of the
population such as children and during pregnancy
• an advisory statement outlining consumption
limits and quantitative compositional labelling
including energy, carbohydrate, caffeine (from 
all sources) and other added substances.
In August 2001, the Australian and New Zealand
Food Standards Council published a new standard 
of the Food Standards Code (standard no. 2.6.4)
governing the labelling of formulated caffeinated
beverages (stimulant drinks) (13). These products
must now carry an advisory statement that the
products contain caffeine and are not recommended
for children, pregnant or breastfeeding women and
individuals sensitive to caffeine. However, the new
labelling does not make any recommendation
regarding appropriate levels of consumption of
energy drinks, nor does it link the consumption of
the beverages with any adverse health effects. At the
same time, health ministers from Australia and New
Zealand permitted the manufacture of stimulant
drinks within Australia.
2.5 Summary
There is a wide range of stimulant drink products
available on the market and the concentration of the
ingredients varies from product to product (Table
2.1). The Committee considered it valid and
appropriate to define those drinks that contain
caffeine, glucuronolactone and taurine as stimulant
drinks. In the Committee’s opinion the term
‘stimulant drinks’ more accurately reflects the market
perception of these products. In considering its
definition the Committee regarded the widely used
term ‘energy drink’ to be ambiguous. Stimulant
drinks are differentiated from isotonic or sports
drinks. The use of stimulant drinks in sport is
considered in more detail in Chapter 4.
There is currently no specific legislation governing
stimulant drinks within the EU, nor is there a
general consensus with regard to the permissible
concentrations of the individual ingredients. Some
countries, including France and Denmark, have a
statutory limit set for caffeine in soft drinks of 150
mg.l -1 and therefore, stimulant drinks are not sold.
Other EU countries including Ireland and the UK,
currently have no specific legislation governing
these products. 
The EU SCF agreed in February 2002 an amendment
to the current labelling legislation and this harmonises
the disparate legislation with regard to labelling of
caffeine content of foods and drinks. The new rules
must come into effect by July 2004.
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“Stimulant drinks
belong to a new class
of food known as
‘functional foods’.”
‘Caffeine is one of
the main active
ingredients found in 
stimulant drinks and
the content per
serving of these
products tends to
be higher than that
of other caffeinated
beverages at
similar volumes.’
3.1 Introduction
The launch of stimulant drinks in 1987 introduced 
a new genre onto the European soft drink market.
Stimulant drinks purport to have ‘functionality’,
including increasing concentration and improving
cognitive performance of the consumer. The basis
of many of the statements made by the
manufacturers of these products lies in the
combination of ingredients used. Stimulant drinks
may contain a variety of components, including
caffeine, guarana, taurine, glucuronolactone and
some of the B vitamins.  
In order to comprehensively assess the health effects
of stimulant drinks, a prior understanding of the
physiological, and potential behavioural effects of
the individual ingredients was necessary. To this end,
the Committee undertook a review of the scientific
literature pertaining to the ingredients of stimulant
drinks. Animal studies and acute human toxicity
studies, where available, were reviewed as well as
human epidemiological data.
3.2 Caffeine
3.2.1 Introduction
Caffeine (1,3,7-trimethylxanthine) is frequently
described as the most widely used psychoactive
substance in the world. Since the discovery of its
chemical structure in 1895, caffeine has become
one of the most comprehensively studied food
ingredients (14). Caffeine is one of a group of
plant alkaloids which occurs naturally in the leaves,
seeds and fruit of more than 60 plant species, of
which cocoa-beans, tea and coffee are the most
well known. The dimethylxanthine derivatives,
theophylline and theobromine, are also found in 
a variety of plants.
3.2.2 Sources of caffeine and caffeine content
Caffeine is present in coffee, tea, chocolate, cola
soft drinks and stimulant drinks. It is also present
in medications, including cold remedies, headache
treatments, diet pills, diuretics and stimulants
(Table 3.1). In order to estimate the consumption
of caffeine by an individual, it is common to
approximate intake by multiplying the number of
cups of coffee, tea or cocoa by an estimated
average caffeine content per cup. However, the
caffeine content of tea and coffee can vary greatly
depending on the method of preparation (e.g.
filter coffee or instant coffee), cup/mug size,
product brand and preferred strength (Table 3.1).
The North/South Ireland Food Consumption Survey
1997-2000 reported that 91% of respondents on
the island drank tea, 55% coffee, 43% carbonated
beverages and 21% diet carbonated beverages (15).
In the UK, the mean caffeine intake from tea, coffee
and carbonated beverages was reported to be 3.98
milligram per kilogram body mass (mg.kg-1 body
mass ) per day. This equates to an approximate intake
of 278 mg per day for a typical 70 kg male (as cited
in Committee on Toxicity of Chemicals in Food,
Consumer Products and the Environment (COT)
Statement, 2001 (16)). In 1995, it was reported that
the consumption of caffeine in the Republic of
Ireland was 3.05 mg.kg-1 body mass per day
(approximate intake of 214 mg per day for a typical
70 kg male) (17).
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mg (range) in a mg.l-1
typical serving (range)
*Average content in a standard 150 ml cup
Instant coffee 43.2 (31.5-51.0) 288 (210-340)
Filter and percolated coffee 27.0 (15.8-32.3) 180 (105-215)
Decaffeinated instant coffee 1.6 (0.5-2.0) 10.7 (3.3-13.3)
Tea – bag brewed 48.9 (36.8-64.5) 326 (245-430)
Tea – loose brewed 15.3 (14.3-15.8) 102 (95-105)
Tea – instant 27.5 (26.3-29.6) 183 (175-197)
Average content per 330 ml can
Coca-Cola 30.7 93
Diet Coke 41.9 127
Pepsi 35.0 106
Pepsi Max 38.0 115
Diet Pepsi 33.3 101
Average content per 250 ml can
American Bull 80.0 320
Dynamite 80.0 320
Indigo Extra 62.5 250
Jolt Cola 213.0 852
Lipovitan B3 50.0 200
Red Bull 80.0 320
Shark Energy Drink 75.0 300
Spiked Silver 80.0 320
V 80.0 320
Average content per typical 30 g
Milk chocolate 5.5 183 
Plain chocolate 10.2 340
White chocolate Not detected Not detected
Source of Caffeine Caffeine Content
* Tea and coffee infusions were prepared according to a standard method involving 200 ml of boiling water and either 1.6 g 
(1 teaspoonful) of loose tea or instant coffee, 2.6 g (1 dessertspoonful) of filtered or percolated coffee or one tea bag. 
Loose and bagged teas were allowed to brew for 5 minutes without stirring, while percolated coffees were prepared by
refluxing the coffee under simulated percolated conditions for 10 minutes. Filter coffees were prepared using a domestic 
coffee filter apparatus (18).
Table 3.1: The caffeine content of some common beverages and foods [adapted from Gray, 1998 (14)
and MAFF Food Surveillance Information Sheet no. 144, 1998 (18)]
3.2.3 Caffeine metabolism
About 90% of the caffeine contained in a cup 
of coffee is cleared from the stomach within 20
minutes of ingestion (19). The caffeine is absorbed
from the gut and does not accumulate in the body
before being rapidly metabolised by the liver and
eliminated (14). In adults, caffeine is virtually
completely metabolised in the liver to its three
dimethylxanthine metabolites, paraxanthine 
(1,7-dimethylxanthine), theobromine 
(3,7-dimethylxanthine) and theophylline 
(1,3-dimethylxanthine), with less than 2% of the
ingested compound recoverable in the urine
unmetabolised (19). 
The average plasma clearance half-life of caffeine 
in an adult is approximately four hours, although 
it should be noted that there is wide individual
variation in metabolism and estimates vary from two
to ten hours (20). In adult males, the caffeine half-
life is reduced by 30 – 50% in smokers compared
with non-smokers, while the half-life is
approximately doubled in women taking oral
contraceptives (21). Pregnant women also experience
increases in the half-life of caffeine (16). 
These variations in half-life mean that smokers, 
if habitual caffeine consumers, need to drink more
caffeine in order to avoid withdrawal symptoms.
Pregnant women, on the other hand, should drink
less caffeine in order to avoid any side effects.
Caffeine has a wide range of pharmacological and
psychological effects (22). The most significant effect
is its role as a stimulant, acting on the central
nervous system (CNS) releasing epinephrine and
increasing the metabolic rate (14).
3.2.4 Potential effects of caffeine
The consumption of caffeine in its many forms is
prevalent worldwide. The daily intake of caffeine in
adults varies enormously, from approximately 220
mg per person per day in the Republic of Ireland 
(17) to greater than 400 mg per person per day in
Sweden and Finland (21). Caffeine is a
pharmacologically active substance and despite
extensive research its effects and health
consequences are ambiguous. 
3.2.4.1 Behavioural effects of acute and chronic
exposure to caffeine
Most studies on the behavioural effects of caffeine
have examined acute responses following a single
large dose. There have been fewer studies on the
effects of habitual or chronic consumption.
Low doses of caffeine (20 – 200 mg per day) have
been associated with effects on mood, such as
feelings of increased energy, imagination, efficiency,
self-confidence, alertness, motivation and
concentration (22). While caffeine is reported to
reduce reaction time during simple tasks, the effect
is thought to be in speeding up performance rather
than increasing mental activity (23, 24). It has also
been reported that regular caffeine consumers, as
compared with non-consumers, have improved
cognitive performance (25).
The acute and chronic effects of caffeine on
cognitive performance, mood, headache and sleep
were reported in 1998 (26). In this study subjects
reported feeling more alert and less tired following
acute ingestion of caffeine, but feeling less alert
with chronic exposure to caffeine. In addition, it
was reported that there was no evidence that
caffeine improved performance either in the
context of acute or chronic use. Performance was
found to be significantly impaired when subjects,
who were habitual caffeine consumers, were
caffeine depleted. It was also concluded that
caffeine rather than enhancing actual performance
in habitual caffeine consumers, merely restored
performance to ‘normal’ levels (i.e. levels of
performance achieved when subjects were free
from caffeine for a protracted period) (26). This was
confirmed in a further study (27).
3.2.4.2 Cardiovascular effects of caffeine 
In spite of numerous studies investigating the link
between caffeine and cardiovascular disease (CVD),
the relationship between them remains uncertain. 
It was reported that individuals who consumed coffee
with a concentration of caffeine of 150 mg in 250 ml
exhibited acute effects on aortic waveform, blood
pressure and arterial stiffness compared with those
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individuals who had consumed a decaffeinated
beverage (28). The authors proposed that this
observation may be an additional vascular mechanism
for the hypertensive effect of caffeine. A number of
researchers have shown that a single high dose of
caffeine (4 – 6 mg.kg-1 body mass , 300 – 400 mg for
average 70 kg male) can cause tachycardia and
increases in blood pressure (23, 29, 30).
The longer-term effects of caffeine on blood pressure
have been studied in several large epidemiological
studies. A meta-analysis of eleven clinical trials has
reported an association between caffeine
consumption and higher blood pressure (31). In a
case-control study of 887 patients, an increased
daytime systolic blood pressure in coffee drinkers
compared with non-drinkers was reported (32).
High-normal blood pressure is a recognised risk
factor for CVD (33). 
Conversely, it was reported in 1998 that habitual
coffee drinkers had significantly lower blood pressure
than non-drinkers at any levels of alcohol use,
cigarette smoking, obesity and glucose intolerance
(34). Similar findings were later reported (35, 36).
Moreover, other studies have demonstrated no effect
of caffeine on blood pressure (37, 38). 
The relationship between caffeine consumption and
myocardial infarction has also been examined. An
increased risk of myocardial infarction with increasing
coffee intake was demonstrated in a group of 858
Massachusetts women with a previous history of
CVD (39). A study conducted in Finland in 2000
reported that coffee drinking does not increase the
risk of CVD or death (40). 
A follow up study to the Scottish Heart Health
Study in 1999, found that male coffee consumers
had a lower risk of heart disease compared with
those who did not consume coffee, even after
adjustment for known risk factors (41). However,
the authors acknowledged that the apparent
benefits of coffee might reflect inadequate
adjustment for lifestyle differences between
consumers and non-consumers, rather than a
protective effect of caffeine per se.
In June 2000, ANZFA produced a ‘Report from the
Expert Working Group on the Safety Aspects of
Dietary Caffeine’ (42). In that report, the literature
pertaining to the relationship between caffeine and
CVD was reviewed. In relation to blood pressure
effects, the report stated that results from long-
term epidemiological studies were ‘inconclusive’
and that if a relationship did exist it was likely to 
be ‘weak and clinically unimportant’. The report
concluded that, based on the evidence published 
in the literature, there was little to substantiate the
theory that caffeine intake at normal consumption
levels contributed to hypertensive disease. However,
one of the original members of the ANZFA working
group produced a minority report in which it was
stated that there was sufficient evidence to
implicate caffeine in a number of health conditions,
including CVD and increased blood pressure (43).
The minority report concluded that habitual use of
caffeine has no demonstrable benefits and that its
consumption leads to physical dependence.
3.2.4.3 Caffeine and diuresis
The diuretic effect of caffeine is well known (17). In
one study, marked diuresis and natriuresis in both
older and younger hypertensive subjects was
observed following a 250 mg dose of caffeine, the
subjects having abstained from caffeine for 2 – 3
weeks prior to the study (44). Another study
demonstrated an increase in diuresis, and urinary
sodium and potassium excretion, within one hour of
caffeine ingestion (45).
In a further study, twelve healthy volunteers were
supplied with a standardised diet for two days.
During the first day, fluid requirement was met by
mineral water. On the following day the same
amount of fluid was supplied but the mineral
water was, in part, replaced by six cups of coffee
containing 642 mg of caffeine in total. An increase
in 24-hour urinary excretion and a corresponding
negative fluid balance, with a concomitant
decrease in body weight, was observed in the
subjects (46).
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3.2.5 Groups for special consideration
3.2.5.1 Caffeine and pregnancy
It has been suggested that caffeine consumption
may affect individuals or sub-groups of the
population, such as pregnant women and children,
who are perceived to be more sensitive to caffeine
than the normal population.
During pregnancy, most women consume caffeine
from one source or another (16). One of the primary
concerns regarding caffeine consumption during
pregnancy is that the half-life of caffeine is increased
threefold, from 4 – 6 hours (in the non-pregnant
woman) to 18 hours late in pregnancy (16). This
delay in caffeine metabolism and excretion results in
prolonged exposure of both the woman and foetus 
to caffeine (47, 48). Caffeine and its metabolites
cross the placenta freely (47, 49, 50), thus exposing
the foetus to higher concentrations of caffeine. 
In animal models, caffeine ingestion during
pregnancy has been demonstrated to cause
skeletal abnormalities, including cleft palate and
delayed ossification (51), foetal growth retardation
(52), and spontaneous abortion (53). However, the
levels of caffeine used in these studies were higher
than those normally consumed by the average
pregnant human adult.
In humans, there is contradictory evidence in the
literature with regard to the effects of caffeine on
pregnancy outcome. Epidemiological studies have
indicated adverse effects of caffeine consumption
during human pregnancy at intakes of greater than
300 mg per day (16). These effects included
spontaneous abortion (54-57) and low birth weight
(54, 58-60). It has also been reported that caffeine
consumption during pregnancy increases the risk of
pre-term birth (61, 62).
However, to the contrary, studies in Finland and
North America found no association between
maternal coffee and caffeine consumption during
human pregnancy and congenital malformations
(63), while another report suggests no discernible
adverse effects of caffeine on the foetus (64). There
is also contradictory evidence on the effect of
caffeine intake on birth weight and it has been
suggested that there is no clear association
between caffeine intake and spontaneous abortion,
delayed conception, pre-term delivery or congenital
malformation (7).
In October 2001, having considered the available
scientific evidence, the UK COT issued a statement on
the effects of caffeine on reproduction (16). In its
conclusions, the Committee suggested that there was
sufficient evidence from research with experimental
animals and from human epidemiological studies, to
suggest that caffeine intakes above 300 mg per day
showed a ‘plausible’ association with low birth weight
and spontaneous abortion. On the basis of this review,
in October 2001 the FSA in the UK advised that
pregnant women limit their daily intake of caffeine to
300 mg per day (65). 
This recommendation is similar to those currently 
in place for caffeine intake during pregnancy (7). 
In the Republic of Ireland the FSAI recommends that
excess consumption of caffeine (in excess of 300 mg
per day) during pregnancy should be discouraged (66).
3.2.5.2 Caffeine and children
There are conflicting data on the effects of caffeine
in children. Caffeine (3 – 5 mg.kg-1 body mass ) was
reported to have small and inconsistent effects on
the classroom behaviour of pre-school children 
(3 – 5 years) (67). At levels in excess of 3 mg.kg-1
body mass , caffeine appeared to cause subjective
effects such as nervousness, jitteriness, stomach
aches and nausea in children who normally
consumed little caffeine (68). Withdrawal symptoms
have been reported in children following exposure 
to levels of caffeine of 120 – 145 mg per day,
equivalent to 3 – 4 cans of a cola drink (69). 
A further study reported that following caffeine
ingestion (2.5 and 5.0 mg.kg-1 body mass )
performances on attention and motor task tests
were enhanced and children described feeling less
‘sluggish’ but somewhat more anxious (70).
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3.2.5.3 Caffeine and individuals with 
caffeine sensitivity
References are frequently made to individuals
who are described as being ‘sensitive to caffeine’.
There is no strict medical definition of this
condition and in most cases the condition itself
is often self-diagnosed and highly subjective.
However, the condition is recognised among
health professionals.
3.2.6 Drug interactions and caffeine 
3.2.6.1 Caffeine and alcohol 
Traditionally, coffee drinking has followed alcohol
intake owing to the widespread belief that it
ameliorates the intoxicating effects of alcohol and
thus has a potential sobering effect. 
The acute behavioural and cardiac effects of
alcohol and caffeine, administered alone and in
combination, have been assessed in humans (71).
Alcohol administered alone showed increased heart
rate, decreased blood pressure, disrupted response
to behavioural tests and increased subject ratings
of drunkenness. Caffeine administered alone
increased blood pressure. However, when given in
combination with alcohol, caffeine partially
decreased the disruptive behavioural effects of
alcohol. By contrast, this combination did not
significantly alter breath alcohol levels or heart rate
levels relative to the effects of each compound
alone. The authors suggested that caffeine did not
actually enhance performance effects, but rather
offset the deterioration in performance effects
observed for alcohol (71). 
In another study the effect of a single dose of
caffeine (200 or 400 mg) on alcohol-induced
driving impairment was examined (72). Caffeine
appeared to increase alertness and improve
reaction time after alcohol-induced consumption in
a laboratory environment. However, caffeine did
not completely counteract alcohol impairment in
the driver.
3.2.6.2 Caffeine consumption and tobacco 
There is a strong interrelationship between coffee
consumption and smoking with 86.4% of smokers
consuming coffee compared with 77.2% of 
non-smokers (73). 
It has been proposed that concomitant smoking and
caffeine consumption is associated with a number of
cancers including ovarian cancer amongst
premenopausal women (74). Several studies have
investigated the role of tobacco smoking and coffee
consumption in pancreatic cancer. However, while
tobacco smoke alone is positively correlated with the
disease, caffeine consumption does not affect this
relationship (75, 76).
3.2.6.3 Caffeine and analgesics and other
prescription medicines
Caffeine has a variety of effects when combined
with medicines. Caffeine has been reported to
enhance the effect of certain analgesics, including
ibuprofen (77). Conversely, it has been shown to
reduce the effectiveness of tranquillisers such as
benzodiazepines (78). 
A reduction in caffeine intake is advised for those
individuals prescribed certain antibiotics, for example
quinolones, since these drugs may inhibit the
elimination of caffeine from the body (79). 
3.2.6.4 Caffeine and recreational drugs
Caffeine, as a competitive antagonist of adenosine
receptors, has been shown to enhance dopaminergic
activity (80). The subjective and behavioural effects
produced by caffeine in humans (enhanced sense of
well-being, delayed sleep, increased energy) are
similar to those of some typical psychomotor
stimulant drugs whose effects may also be mediated
by interference with dopaminergic pathways.
In a recent study of the acute and chronic effects of
MDMA (3-4 methylenedioxymethamphetamine or
Ecstasy) in rats, the possible interactions of caffeine
and MDMA were examined (81). Caffeine (5 mg.kg
body mass -1) exacerbated the acute hyperthermic
response to MDMA and tended to increase the loss
of serotonin (forebrain 5-HT or hydroxytryptamine)
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and 5-HIAA (5-hydroxyindoleacetic acid). Thus,
caffeine may aggravate the hyperthermic and
neurotoxic effects of MDMA, possibly through a
mechanism involving dopamine release. It was also
found that higher doses of caffeine (10 and 20
mg.kg-1 body mass ) when co-administered with
MDMA (20 mg.kg-1 body mass ) had lethal effects 
in experimental animals.
These results suggest that caffeine enhances the
effects of MDMA and could possibly exacerbate
dehydration due to separate diuretic effects.
3.2.7 Caffeine – summary
Caffeine is one of the main active ingredients found
in stimulant drinks and the content per serving of
these products (60 to 80 mg per 250 ml can) tends
to be higher than that of other caffeinated
beverages at similar volumes (Tables 2.1 and 3.1).
The use of caffeine in its many forms is universal.
However, in spite of extensive research, the evidence
with regard to the health implications of the
ingredient remains inconclusive.
High acute intakes of caffeine (4 – 6 mg.kg-1 body
mass , 300 – 400 mg for average 70 kg male) are
associated with tachycardia and acute increases in
blood pressure. The longer-term risks, or indeed
possible benefits, of caffeine in relation to CVD are
less clear. The evidence for an association of habitual
caffeine intake with increased blood pressure is
conflicting. Increased blood pressure is a known risk
factor for heart disease and stroke, and individuals
with high blood pressure are generally advised to
reduce their caffeine consumption. 
The possible adverse effects of increased caffeine
on pregnancy have recently been reviewed by the
COT in the UK. On the basis of a possible association
of high caffeine intake (in excess of 300 mg per
day) with low birth weight and spontaneous abortion,
the FSA in the UK recommend that pregnant
women should limit their daily intake of caffeine to
300 mg (equivalent to about four average cups of
coffee, six average cups of tea, eight cans of
regular soft drink or four cans of stimulant drinks).
The FSAI makes a similar recommendation.
In children single doses of caffeine up to 10 mg.kg-1
body mass have been shown to have either no
effect or small, inconsistent effects on mood,
behavioural, cognitive and motor functions. Some 
of the effects may be interpreted as being beneficial.
However, some studies have indicated that a dose of
5 mg.kg-1 body mass (equivalent to 150 mg caffeine
per day, 4 – 5 cans of a cola drink, for a 10 year-old,
30 kg child) increased arousal, irritability, nervousness
or anxiety in some children, particularly if they were
normally low consumers of caffeine.
Caffeine has been shown to partially ameliorate the
effects of alcohol but enhance the effect of
psychomotor stimulant drugs. As stimulant drinks are
commonly consumed with alcohol and in social
settings, these combined effects may be of
significance when considering the effects of
stimulant drinks in their contextual settings. 
3.3 Guarana
3.3.1 Introduction
Guarana, a native South American plant, contains
guaranine, a substance chemically similar to caffeine
with comparable stimulant effects. Guarana (Paullinia
cupana) is often added to stimulant drinks, either in
combination with caffeine or on its own.
3.3.2 Sources of guarana
Guarana, a berry that grows in Venezuela and the
northern parts of Brazil, is used in drinks that
contain extract from the crushed guarana seeds
and are commonly consumed in Brazil. The use of
guarana as an ingredient in beverages is becoming
increasingly more popular in Europe, particularly in
energy or stimulant drinks. 
The stimulant effect of guarana is related to its
caffeine content; one gram of guarana contains as
much caffeine (40 mg) as a medium strength cup of
coffee (12). The precise source and nature of the
stimulant activity of guarana is not well
understood. However, it has been reported that
guarana exerts a more prolonged effect than an
equivalent amount of caffeine, even though the
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stimulant action has been attributed to the
presence of caffeine. This effect is thought to be
owing to the complexing of caffeine with
condensed tannins in guarana and to the presence
of fats and saponins in the seeds. This may affect
the solubility and absorption of caffeine in the
gastrointestinal tract (82). In determining the
overall caffeine content of a beverage, the guarana
content must be taken into account along with the
caffeine content.
3.3.3 Potential effects of guarana
The physiological effects of guarana may be
attributed to its caffeine content and hence many
of the observed consequences of guarana
consumption will be similar to those discussed in
the previous section on caffeine. 
A review of the literature indicates that guarana 
is often used in conjunction with other herbal
preparations such as yerba matte and ma huang 
as a weight loss agent in humans (83, 84). Results
from these studies have shown these preparations
to be effective, however, the authors acknowledge
that the effects of long-term use of these
substances are not known.
Suspected caffeine and ephedrine toxicity in dogs
following supplementation with guarana and ma
huang has been reported (85). The dogs were
given guarana in the range of 4.4 – 296.2 mg.kg-1
body mass and the symptoms observed ranged
from vomiting and tachycardia, to death. The
minimum dose at which death was reported was
19.1 mg guarana.kg-1 body mass . Conversely, a
study in 1998 reported that guarana was non-toxic
in laboratory animals after acute administration at
high doses (1 – 2 kg.kg-1 body mass ) and chronic
treatment with lower doses (86). There is also
some evidence that guarana may inhibit platelet
aggregation in mammalian blood although the
research is limited (87). 
In 2001, the death of an Australian woman
following consumption of a guarana-containing
health drink product was reported (88). The
caffeine concentration in the bottle of ‘Race 2003
Energy Blast’ (55 ml) was subsequently determined
to be 10 g.l -1 (equivalent to 35 cups of coffee). 
The woman, who had an underlying cardiac
abnormality, mitral valve prolapse, had been
previously advised by her doctor to reduce her daily
caffeine intake, and on the day of her death had
consumed only the guarana health drink. This
report recommended that more careful regulation,
including appropriate labelling of so-called natural
or herbal products, was warranted.
In May 2001, the FDA in the USA informed
manufacturers of foods and drinks containing
guarana and other herbal substances including
echinachea and ginseng, that the use of these herbs
in food products was no longer permitted, forcing
the withdrawal of a number of stimulant drink
products from the USA market (89). The withdrawal
of these products was based on USA legislation that
states that manufacturers must prove that all
ingredients are safe for use in foods, even if they
have received prior approval for medical use. The
manufacturers of the products involved will now
have to produce scientific evidence to the FDA that
their products are safe. 
The FSA in the UK has asked the EU to investigate
the use of guarana, and other herbs, as stimulants
and flavourings in stimulant drinks.
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3.3.4 Guarana – summary
There is very little information in the literature with
regard to the effects of guarana, although it is
conceivable that products high in guarana will
have similar physiological and behavioural effects
as caffeine.
It is highly likely that the majority of the public do
not realise that guarana containing products are in
fact high in caffeine. This is of concern particularly
to those individuals who may be caffeine sensitive
and adequate labelling of guarana containing
products is, therefore, essential. Since the release
and uptake of caffeine from guarana is the same as
for preparations containing free caffeine (90), it is
clear that the guarana content of drinks must be
taken into account when estimating total caffeine. 
3.4 Taurine
3.4.1 Introduction
Taurine (2-amino ethanesulphonic acid) is added to
stimulant drinks at concentrations in the range of
2000 – 4000 mg.l -1 (Table 2.1). It is naturally
present in the diet and is a normal metabolite in
humans, being synthesised in the body from the
amino acid cysteine, or other sulphur or cysteine
containing compounds. 
3.4.2 Sources of taurine
Taurine is sometimes referred to as a ‘conditionally
essential’ amino acid in adults based on evidence
which indicates that in times of severe stress, such
as during intense physical exercise, the stores of the
amino acid become depleted. However, under
normal physiological circumstances, taurine is very
highly conserved in the adult human body and is
present in large quantities (91). Indeed, it has been
estimated that a 70 kg human is likely to contain
up to 70 g of taurine (91, 92). The mean daily
intake of taurine from the diet is estimated to be
approximately 400 mg per day (7), with sea fish
and red meat being the richest sources.
Taurine is thought to play an extensive role in
numerous physiological processes, including the
formation of bile salts, and modulation of calcium
flux and neuronal excitability (92). The physiological
roles of taurine are summarised in Table 3.2.
In adult humans, taurine can be synthesised within
the body but, as outlined above, may also be
obtained from the diet, particularly from meats and
fish (17). Unlike most other amino acids, it is not
used in protein synthesis in the human body, but is
found mostly as the free amino acid or as simple
peptides, dissolved in the cytosol and bound to cell
membranes (91). It occurs in high concentrations in
skeletal muscle, cardiac muscle, retinal tissues, the
central nervous system (CNS) and the brain, white
blood cells and platelets. Taurine is also considered to
be essential for normal development of human
infants and consequently, several manufacturers add
taurine to infant feeding formulae (91, 92).
3.4.3 Potential effects of taurine
A review of the literature indicates that many of
the putative functions of taurine appear to be
physiologically beneficial (Table 3.3). However,
there are some limited data to suggest that, under
certain conditions, exposure of cells or human
embryos to very high concentrations of taurine
may be harmful (94, 95). It is unlikely that these
findings will have any relevance to humans
consuming taurine by the oral route.
A search of the literature shows little evidence to
suggest that taurine is a risk to human health.
However, there are no published studies of the
effects of high intakes of taurine in healthy adults,
and no studies at all in children or adolescents.
The available published toxicological data for
humans are summarised in Table 3.3. These studies
have been carried out in adults who were
undergoing experimental treatment for defined
medical disorders.  
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There are some data to suggest that taurine may
mitigate against some of the adverse consequences
of ethanol consumption, and as such, may possibly
encourage greater alcohol intake (100).  
Taurine, when consumed with alcohol, has been
shown to reduce sleep-time in mice (101-103).
However, there are no studies of the effects of
ethanol with concomitant taurine intake on sleep
time in human subjects. Changes in locomotor
activity following alcohol consumption and 
supplementation with taurine have also been
demonstrated in laboratory animals (104, 105).
Alcohol has a negative effect on taurine homeostasis
in humans. Chronic alcohol abusers were reported to
have significant increases in plasma taurine
concentration seven days following withdrawal from
alcohol. Furthermore, an oral dose of ethanol (0.8
g.kg-1 body mass ) decreased plasma taurine content
90 minutes after administration (106). 
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Cardiovascular
Central nervous system
Retina
Liver
Reproductive system
Muscle
Others
System Action
Table 3.2 Putative physiological functions of taurine [adapted from Huxtable (91) and Bkaily et al. (93)] 
Antiarrhythymic properties
Hypotensive action
Modulation of calcium channel action
Retardation of lesion development in calcium overload cardiomyopathy
Increase resistance of platelets to aggregation
Positive inotropic effect in heart muscle
Protection against calcium overload in hypoxic injury
Anti-convulsant properties
Modulator of neuronal excitability
Maintenance of cerebellar function
Thermoregulation 
Anti-aggressive actions
Central regulation of cardiorespiratory responses
Alteration to sleeping duration
Resistance to anoxia/hypoxia
Altered motor behaviour
Anti-tremor actions
Suppression of eating and drinking
Maintenance of structure and functions
Bile salt synthesis
Sperm motility
Membrane stability
Modulator of neurotransmitters and hormones
Osmoregulation
Stimulation of glycolysis and glycogenesis
Antioxidant effects
Attenuation of hypercholesterolaemia
Cell proliferation and viability
Conjugation of xenobiotics prior to excretion
3.4.4 Taurine – summary
Taurine is an amino acid and its main function in the
human body is in the synthesis of bile salts. In
addition, taurine can conjugate with various
xenobiotics and aid in their excretion. While some
animals, such as the cat, require taurine in the diet,
humans synthesise adequate supplies of taurine and
do not rely on dietary sources.
Taurine has been shown to have beneficial health
effects, including decreasing blood pressure. 
A thorough search of the literature revealed no
published studies of any negative physiological
effects of high intakes of taurine in healthy adults.  
There are no studies of the effects of taurine
supplementation in adult humans and, apart from
some papers discussing the effects of the
consumption of stimulant drinks (3), there are few
studies on the interactions of taurine with other
ingredients contained in stimulant drinks (such as
caffeine and glucuronolactone) or with substances
such as alcohol or drugs. While it is not possible to
extrapolate results of animal studies to the human
condition, the interactions of taurine and alcohol are
particularly pertinent in light of the evidence that
stimulant drinks are regularly consumed with alcohol
(Chapters 5 and 6). Further investigations in humans
are required.
3.5 Glucuronolactone
3.5.1 Introduction
Glucuronolactone is a naturally occurring
metabolite formed from glucose. Not all stimulant
drinks contain glucuronolactone (Table 2.1),
however, the concentration when present ranges
from 250 to 2500 mg.l -1. 
3.5.2 Sources of glucuronolactone
Glucuronolactone is only found naturally in a small
number of foods, of which wine is the richest natural
source. It has been reported, based on USA estimates,
that consumers of two 250 ml cans of stimulant drinks
containing 2400 mg.l -1 could exceed glucuronolactone
intake from other food sources by up to 500-fold (7).
At physiological pH, glucuronolactone is in
equilibrium with glucuronic acid, its immediate
precursor. Animals, including rats and mice, which
synthesise vitamin C, do so by converting glucuronic
acid, either to gulonic acid or to glucuronolactone,
then to gulonolactone, and finally to ascorbic acid.
These animals can also convert orally administered
glucuronolactone to vitamin C (107). As humans do
not possess the metabolic pathway to synthesise
vitamin C, rats and mice are unsuitable models for
the study of the effects of glucuronolactone in man.
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Ikeda (1977) (96)
Mantovani and DeVivo 
(1977) (97)
Franconi et al. (1985) (98)
Kendler (1989) (99)
Reference Dose Toxicological endpoint
Table 3.3 Summary of taurine toxicity studies in humans [adapted from the ANZFA Full Assessment
Report and Regulation Impact Assessment. Application A349 Formulated Caffeinated Beverages (11)]
3000 mg per day (3 x 1000 mg per
day) for 7 days in patients
undergoing alcohol withdrawal
Single doses of 375 mg per day to
8000 mg per day in epileptic adults
1500 mg per day for 90 days in
adults with and without insulin
dependent diabetes mellitus
3000 mg or 6000 mg per day for 6
weeks in adult patients with mild
hypertension
Fewer psychotic episodes in patients
who were supplemented with
taurine compared with non-
supplemented controls.
No evidence of adverse effects
No evidence of adverse effects
No evidence of adverse effects
Decreased blood pressure in
hypertensives
No evidence of adverse effects
3.5.3 Potential effects of glucuronolactone
There has been little research examining the effects 
of glucuronolactone in humans. The available data
indicate that when glucuronolactone is administered
orally to humans it is rapidly absorbed, metabolised and
excreted as glucaric acid, xylitol and L-xylulose (108).
A number of animal studies using rat, mouse and
dog models have examined the metabolism of
glucuronolactone. However, given that the
metabolic pathway of glucaric acid in these animals
is markedly different from that in humans, the
relevance of such studies to human
glucuronolactone metabolism is unknown.
Some toxicity studies have been carried out in animal
models. The SCF report in 1999 concluded the
following:
“The available toxicity studies are extremely limited.
Acute toxicity studies have been carried out in rat,
mouse, dog, rabbit and cat by oral, intravenous,
intraperitoneal and subcutaneous routes. It
[glucuronolactone] is of low acute toxicity, with the
oral route being the least toxic” (7).
The effect of glucuronolactone supplementation on
rat longevity has been examined (109). The study
was designed to test the hypothesis that, as an
inhibitor of ß-glucuronidase, glucuronolactone would
increase longevity by increasing the rate of excretion
of xenobiotics as glucuronides. Administration of
glucuronolactone in drinking water had no effect on
fluid intake, bodyweight, time of death, or cause of
death as determined by autopsy. 
The effect of glucuronolactone on the biochemical
changes produced in rats during exercise has also
been examined (110). The study concluded that
glucuronolactone inhibited the synthesis of a number
of undesirable metabolites formed as a result of
intensive exercise. It also prevented a decrease in
blood sugar levels and in hepatic glycogen while
increasing the length of time that the rats exercised
before exhaustion.
3.5.4 Glucuronolactone - summary
The intake of glucuronolactone from consumption of
some stimulant drinks may be much greater than
that from the rest of the diet and there appears to
be little or no information available for risk
assessment of glucuronolactone at these levels in
humans. Furthermore, the only study in which high
levels of glucuronolactone have been added to the
diet is in the rat model. Since rats and mice
metabolise glucuronolactone differently from
humans, toxicity studies using a more suitable
model, such as the guinea pig, are warranted. 
There is no information available on the possible
interaction of glucuronolactone and alcohol
metabolism.
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‘There is little
evidence to suggest
that taurine is a risk
to human health.
However, there are
no published studies
of high intakes of
taurine in healthy
adults, and no studies
at all in children 
or adolescents’.
‘Stimulant drinks are 
associated, and
actively promoted,
in sporting contexts.
They are not,
however, suitable
for use as rehydration
drinks in association
with sport or exercise.’
4.1 Introduction
Extensive research has been carried out on the
health effects of some of the individual ingredients
of stimulant drink products, such as caffeine.
However, an examination of the literature reveals
limited studies of the combined effects of these
ingredients, or their combined effects under the
circumstances in which they are consumed. Of 
the studies that have been conducted, the
performance effects only of consumption of
stimulant drinks have been examined (3).
Qualitative research conducted for the purposes of
this report confirms that the public has a number
of concerns regarding the possible adverse health
effects of stimulant drinks (Chapter 5). 
4.2 Physiological Effects of Stimulant
Drinks under the Circumstances in
which they are Consumed
4.2.1 Sport
Stimulant drinks are promoted in such a way as to
suggest that they may be beneficial to individuals
partaking in active pursuits. Certain stimulant drink
products are advertised overtly in sporting
environments or with sporting overtures (Chapter 7).
The main ingredients in stimulant drinks purported
to influence body physiology during sport are
caffeine and carbohydrate.
4.2.1.1 Caffeine during exercise
The use of caffeine in sport is a contentious issue.
IOC considers that a urinary concentration of
caffeine of 12 mg.l -1 in urine represents a positive
drug test. However, caffeine is shown to have
performance-enhancing effects at concentrations
that would result in urinary excretion below 12
mg.l -1 as set by the IOC (111).
Caffeine is reported to be most beneficial in
endurance-type exercise activities (i.e. activities
lasting more than 30 minutes). The physiological
bases of the performance-enhancing effects of
caffeine are not known. Many theories have been
put forward including, a possible increase in
circulating adrenaline and/or sympathetic nervous
activity. One theory proposes that caffeine
influences adipose tissue metabolism. This results
in an increase in the plasma concentration and
subsequent uptake by, and oxidation of, free fatty
acids leading to a reduction in the rate of glycogen
use in skeletal muscle. Another putative
mechanism for caffeine action is the creation of a
more favourable intracellular ionic environment
facilitating the development of a contractile force
in muscle (111).
A sports person using caffeine as an ergogenic aid
would typically consumer 4 – 5 mg.kg-1 body mass
of caffeine (approximately 350 mg of caffeine,
equivalent to 4 cans of a typical stimulant drink) 60
– 90 minutes prior to the event. This allows time
for the caffeine to be absorbed into the circulation
and reach an effective concentration in the blood.
At this level of intake, caffeine acts as a diuretic.
Adequate fluid intake is recommended to offset
potential dehydration (112).
Caffeine-induced diuresis during exercise may result
in excessive fluid and electrolyte loss, a decrease in
plasma volume and reduced ability to thermoregulate
leading to a higher body temperature (112). There
are, however, some reports which suggest that urine
volume, sweat loss, plasma volume, nor core
temperature is altered during exercise following
caffeine ingestion (113, 114), although these results
remain unconfirmed.
Given the limited information on the diuretic effects
of stimulant drinks, it is the view of the Committee
that in the immediate period following physical
exercise, caffeine-containing stimulant drinks are not
suitable as an oral rehydration aid.
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4.2.1.2 Carbohydrate during exercise
It has been established that the ingestion of a
carbohydrate-containing beverage during exercise
can maintain blood glucose levels, and the required
carbohydrate oxidation, to sustain high-intensity
exercise performance (112). 
Pre-exercise consumption of a fluid beverage
designed to enhance sports performance is not
straightforward. Taken 40 minutes prior to
exercise, the ingestion of a beverage containing 
40 g of a simple carbohydrate (250 ml of stimulant
drink contains approximately 30 g of carbohydrate,
Table 2.1), invokes a rapid decrease in blood
glucose to hypoglycaemic levels and a higher rate
of glycogen utilisation during exercise, thereby
decreasing the exercise output. The same quantity
of carbohydrate beverage consumed only five
minutes prior to exercise has little, if any, effect on
blood glucose or glycogen utilisation and increases
the total amount of work performed (115).
Carbohydrate feeding during exercise is
acknowledged to be beneficial to sports
performance (116). The consumption of a stimulant
drink could provide a readily available source of
energy intake in the form of carbohydrate (400 kJ
per 250 ml serving of a typical stimulant drink)
during exercise. However, it is important to note that
high carbohydrate beverages, such as stimulant
drinks, are hypertonic to blood plasma and the
majority of body fluids and will thereby decrease the
rate of gastric emptying and induce a net secretion
of water from the body into the upper part of the
small intestine prior to absorption. This removal of
body water is, in effect, a form of dehydration and
the resultant increase in intestinal water may lead to
gastrointestinal disturbance and discomfort (112). 
In general, isotonic or sports beverages contain a
carbohydrate concentration isotonic with respect to
blood plasma and do not elicit these effects and are,
therefore, promoted as effective modes of
carbohydrate delivery. 
In recovery from exercise, there is a two-phase
restoration of body glycogen stores. Glycogen
resynthesis occurs most rapidly within the first six
hours, provided carbohydrate is consumed at a
rate of 1 g.kg-1 body mass every two hours during
this period. If the replenishment of body glycogen
post-exercise were the intended use for stimulant
drinks, for an adult person weighing 75 kg, this
would be equivalent to the consumption of
approximately 750 ml of a stimulant drink
(equivalent to three 250 ml cans) every two hours
(112). However, as noted in section 4.2.1.1, the
large intake of caffeine contained in a typical
stimulant drink (equivalent to approximately 3.2
mg.kg-1 body mass every two hours) would
probably have a negative effect on the restoration
of fluid balance and therefore the use of stimulant
drinks for this purpose would not be
recommended (112).
4.2.1.3 Interaction between caffeine and
carbohydrate upon exercise performance
Reviews of the effect of caffeine upon exercise
performance show the performance-enhancing
effect of caffeine to be highly variable (111, 117).
However, a limited number of studies have evaluated
the interaction between caffeine and carbohydrate
or the performance-enhancing effect of a caffeine-
containing carbohydrate beverage. In one study, the
addition of caffeine to a carbohydrate-containing
solution was found to have a positive effect on
performance during a high intensity cycle exercise
lasting approximately one hour (118). These data
reveal that, when combined with carbohydrate,
relatively low doses of caffeine can enhance
endurance-exercise performance. 
4.2.1.4 Stimulant drinks and exercise
The effect of a stimulant drink on performance in
endurance athletes has been examined in a number
of limited small-scale studies, many of which have
received endorsement from the manufacturer of a
stimulant drink product. These studies suggest an
improved performance following consumption of
stimulant drinks (119, 120).
In one randomised crossover study, subjects were
given either a drink containing: carbohydrate and
caffeine, but without taurine and glucuronolactone;
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carbohydrate but without taurine, glucuronolactone,
or caffeine; or carbohydrate with taurine,
glucuronolactone and caffeine (119). The results
showed a significant increase in performance
during exercise in the group receiving the taurine
containing drink. The recipients of the taurine
containing drinks also demonstrated lower heart
rates and catecholamine levels resulting in
prolonged exercise endurance, which was observed
up to 24 hours later (119).
Another study investigated the parameters of
cardiac contractility in 13 endurance-trained
athletes following consumption of a stimulant
drink containing: carbohydrate, caffeine and
taurine; carbohydrate and caffeine but without
taurine; and a placebo containing carbohydrate,
but without caffeine and taurine (120). The results
demonstrated an effect of the stimulant drink on
cardiac parameters after exercise and the authors
suggested that the observed effects might explain
the improved performance and lower heart rate
observed in previous studies (120).
4.2.2 Social context
Quantitative and qualitative analyses (Chapters 6
and 7) indicate that stimulant drinks are widely
consumed in social settings such as in public
houses and clubs, both on their own but mainly
with alcohol. 
4.2.2.1 Alcohol
The physiological and pharmacological effects of
combined caffeine and alcohol were previously
discussed in section 3.2.6 of this report.
There is considerable concern that the consumption
of alcohol and stimulant drinks may cause transient
behavioural effects, including increased aggression,
as well as increasing the ability of individuals to
drink alcohol for longer periods of time (Chapter 5).
The latter effect in itself is a cause of concern as
this may result in individuals consuming larger
quantities of alcohol. A search of the literature
revealed no information with regard to any published
reports of the health effects of the concomitant
consumption of stimulant drinks and alcohol.
The above concerns are supported by findings from
the qualitative analysis discussed in more detail in
Chapter 5. This analysis revealed that parents of
consumers perceived that stimulant drinks
encouraged greater consumption of alcohol. In
recent years, the increase in street violence has
been associated with an increased consumption 
of alcohol. These concerns have led to the
establishment of an inquiry within the Department
of Justice, Equality and Law Reform in the Republic
of Ireland. The Commission on Liquor Licensing is
currently continuing with its deliberations (121).
In summer 2001, the Swedish National Food
Authority recommended that stimulant drinks
should not be consumed with alcohol. This
recommendation followed the death of a young
woman from arrhythmia who had, reportedly,
consumed a number of stimulant drinks with
alcohol (122). The Swedish authorities are currently
carrying out a further examination of the effects of
stimulant drinks and alcohol.
4.2.2.2 Recreational drugs
Stimulant drinks may be used in the ‘club’ scene
where drugs, including ‘recreational’ drugs (Ecstasy
(MDMA) and cocaine) may also be used. Thus, the
Committee considered it necessary to investigate
any link between stimulant drinks and recreational
drugs. The interaction of caffeine and drugs,
including recreational drugs, has been previously
discussed in section 3.2.6. 
While it may not be possible to directly extrapolate
research on animals to humans, the evidence
shows enhanced toxicity of MDMA when co-
administered with caffeine (81). This may give
cause for further concern where stimulant drinks
are being consumed with drugs of abuse,
especially amphetamine-like drugs. 
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4.3 Behavioural/Performance Effects
of Stimulant Drinks 
As already mentioned, there are little published
data in the literature on the behavioural and
performance effects of stimulant drinks.
In a study of the effect of a stimulant drink on
cognitive performance in humans, no effect on
reaction time in males was observed while females
exhibited a small improvement in reaction time
following ingestion of the stimulant drink (250 ml
or one can) compared with a placebo (123). 
It has also been reported that a stimulant drink
significantly improved concentration, reaction time,
memory, mood, as well as aerobic and anaerobic
endurance (124).
The effect of a stimulant drink on driving
performance has been investigated (125, 126). 
In the latter study, the researchers examined reaction
time and sleepiness in 12 sleep-deprived individuals
participating in a simulated highway driving
experiment. Among the control subjects, sleepiness
was particularly evident 30 – 60 minutes into a two-
hour drive. However, subjects who had consumed
the drink (500 ml, equivalent to two cans), showed 
a significant reduction in lane drift and also
demonstrated improved reaction time (126).
In 2001, ‘mania’ associated with a stimulant drink
was reported in a letter to the Canadian Journal of
Psychiatry (127). In this letter, the authors suggested
that stimulant drinks might be associated with
pathological mood and behavioural changes in
vulnerable patients such as those with bipolar
illnesses. These observations followed a report of
increased euphoria, hyperactivity and insomnia in a
patient suffering from bipolar disorder who had
consumed three cans of a stimulant drink.
4.4 Acute Physiological Effects 
of Stimulant Drinks 
There is particular concern that some individuals
who may have increased sensitivity to the
ingredients of stimulant drinks, particularly
caffeine, may have an acute physiological response
on consuming the products.
While there are no reports in the literature
regarding the adverse physiological effects of the
combined ingredients of stimulant drinks, one
recent study examined the effect of a stimulant
drink on blood pressure and arterial stiffness in a
laboratory setting (128). The stimulant drink (500
ml, equivalent to two cans) was administered to
eight healthy volunteers and blood pressure and
heart rate were monitored over the course of a
two-hour period. By observing arterial stiffness via
pulse wave velocity, the authors suggested that the
stimulant drink had a dual action on the
cardiovascular system, with taurine having a
vasodilatory effect in addition to the known
vasoconstrictor effect of caffeine. They concluded
from their data that the stimulant drink had acute
cardiovascular effects.
While this is the only study in the literature that
specifically looks at the possible adverse health
effects of a stimulant drink, the study design did
not provide for a control or placebo being
incorporated into the research. In considering the
physiological effects of stimulant drinks,
cognisance must be given to the potential adverse
effects of the individual ingredients as discussed in
Chapter 3.
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4.5 Summary
Peer reviewed studies on the physiological and
behavioural effects of the combined ingredients of
stimulant drinks are very limited and these areas
require further study. Qualitative research suggests
that consumption of these products is associated
with effects such as disorientation, sleeplessness
and increased heart rate. 
While the consumption of stimulant drinks on their
own is an issue, the context or circumstances
under which they are consumed is also relevant. 
Stimulant drinks are associated, and actively
promoted, in sporting contexts. Caffeine can
enhance performance in certain sports. However,
stimulant drinks are not suitable for use as
rehydration drinks in association with sport or
exercise. Unlike isotonic sports drinks, stimulant
drinks do not meet the recommended
compositional requirements (with respect to
osmolarity and concentrations of caffeine,
carbohydrate and electrolytes). Little is known
about the possible adverse effects on exercise
performance and fluid balance during sport and
exercise occurring from the interaction of the
principal ingredients contained in stimulant drinks
and further research is necessary.
Results of qualitative and quantitative analyses
indicate that stimulant drinks are widely consumed
as mixers for alcoholic beverages. There is little
published information on the possible adverse
health effect of stimulant drinks with alcohol,
although there is concern that increased alcohol
intake, in combination with stimulant drinks, may
have behavioural effects. As they are regularly used
in social settings, the possible adverse effects of
the interaction of stimulant drinks with recreational
drugs (e.g. Ecstasy) must also be considered.
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‘The majority of
participants in the
groups perceived
that the primary
mode of
consumption of
stimulant drinks
was with alcohol.’
5.1 Introduction
In order to address consumer health concerns and
perceptions with regard to stimulant drinks, a
qualitative study of the attitudes of the public in
relation to stimulant drinks was undertaken. The
results of this analysis were then set in a social
context of general lifestyle and drinking behaviour. A
summary of the study is outlined below and the full
text of the qualitative study can be obtained on the
FSPB website at:
URL:http://www.safefoodonline.com/publications/pubs.
html
5.2 Methodology 
Focus groups were used in the research. Research
took place in November 2001 and due to time
restrictions all sessions were conducted in Dublin.
Three groups of people were identified as being
central to this issue:
• parents of young adults in the core target market 
(aged 18 - 24 years) who still resided in the parental 
home. Fathers and mothers of the economic groupings,
ABC1, and mothers, CD2, were interviewed.
• consumers in the core target market (aged 18 – 24 
years), ABC1 males and C1C2 females.
• young consumers under the age of the core target 
market (aged 12 – 15 years) were also included. 
In this case, five groups were interviewed: ABC1
males aged 12 & 13 years; C2D females aged 13
years; ABC1 males aged 14 & 15 years; C2D
females aged 12 & 13 years and ABC1 females
aged 15 years*.
5.3 Results
5.3.1 Concerns of parents of consumers
Parents acknowledged that their adult children have
a short-term focus, living for today and not planning
for the future, simultaneously spending their
earnings on their social life.
Parents were aware of stimulant drinks and specific
brands and generally held a negative view of them.
The majority of parents had concerns about
perceived health issues pertaining to stimulant
drinks and had heard, and were able to recount,
many anecdotes.
The main parental concern was the consumption of
stimulant drinks with alcohol. Parents believed that
stimulant drinks were not ‘safe’ when consumed with
alcohol because they ‘stimulated’ the drinker unlike
other available mixers, and also allowed for further
alcohol consumption. Parents believed that stimulant
drinks adversely affected how the alcohol was
assimilated by the drinker, resulting in individuals who
became drunk in a ‘different way’ to the norm.
Some parents expressed concern that consumption
of stimulant drinks could lead to violence, while
other parents stated that inability to sleep
following consumption of stimulant drinks was a
matter for concern.
5.3.2 Concerns of young adult consumers, 
18 – 24 years
Among this age group, there is a strong drinking
culture across gender and class. Drinking to excess,
to the point of becoming drunk with reduced
control, is at least a weekly event.
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* Social class definitions are based on the occupation of the main income earner in a household and are defined as follows:
Grade A: Upper middle class, e.g. medical doctor, bank manager, university professor
Grade B: Middle class, e.g. college lecturer, pharmacist
Grade C1: Lower middle class, e.g. bank clerk, Garda sergeant
Grade C2: Skilled working class, e.g. carpenter, electrician
Grade D: Other working class, e.g. fisherman, milkman
Grade F: Farmer
The consumption of stimulant drinks had a stronger
bias in the male group, who saw it as a socially
acceptable way to drink vodka. None claimed it as
their main drink, and most respondents claimed to
drink it late into a drinking session rather than at the
beginning. Most claimed to drink less stimulant
drinks now than they had one year or eighteen
months ago. 
All participants in this age group expressed some
level of concern about stimulant drinks. Consumers
enjoyed the stimulatory effect of stimulant drinks
particularly with alcohol. However, their enjoyment
of the combination was less than that with other
alcohol combinations. Their reported ability to enjoy
stimulant drinks was affected by the background
concerns of their being slightly dangerous and this
was likely to curtail excessive consumption.
Consumers also expressed concern in relation to
the caffeine content of the drinks. Some consumers
reported the inability to sleep following
consumption of stimulant drinks and this was seen
as a negative attribute.
5.3.3 Concerns of young consumers
There were marked differences in the behaviour of
the groups within this category according to age,
gender and social class profiles, particularly in
relation to personal freedom, alcohol consumption
and stimulant drinks.
All young consumers were aware of stimulant drinks
and a particular brand was mentioned frequently.
Almost all of the groups reported having tried
stimulant drinks. Young consumers perceived
stimulant drinks to fill a gap between soft drinks and
alcohol and found it attractive because they
considered them to be slightly ‘illicit’ due to the
stories they had heard and its close association with
adult drinking.
5.4 Summary
The majority of participants in the groups perceived
that the primary mode of consumption of stimulant
drinks was with alcohol. However, both parents and
consumers of stimulant drinks believed that the use
of stimulant drinks with alcohol was no longer the
‘trendy’ drink that it had once been, although there
remained a core group of consumers of stimulant
drinks with alcohol. This group was male who
tended to see stimulant drinks as a more credible
mixer for vodka and other spirits.
The main concerns vis à vis stimulant drinks were its
consumption with alcohol, the perceived ‘high’
caffeine content, and the sense of ambiguity and
uncertainty about what the other ingredients were
and how they affected the body. The uncertainty over
what these ingredients were, or their effects, was also
raised. Anecdotes also played a large part in moulding
opinions and beliefs surrounding the drinks.
Parents were more actively concerned than
consumers, the latter acknowledging the risks but
continuing to drink the product. In general, there
was a sense that stimulant drinks were no longer
the ‘must have’ drink of the majority of young
adults and with that, a perception that any health
risks had diminished.
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‘Parents were more
actively concerned
than consumers, the
latter acknowledging
the risks but
continuing to drink
the product.’
‘The average number
of cans consumed
by ‘ever’ consumers
in a single session
was three.’
6.1 Introduction
Results from the qualitative research into consumer
perceptions indicated that stimulant drinks are widely
consumed, mainly with alcohol, and by young males
in particular. The Committee considered it necessary
to establish the consumption patterns and levels of
peak consumption of stimulant drinks being
consumed on the island of Ireland before any further
assessment could be made of the health effects of
the drinks. To this end, a quantitative study was
commissioned to establish consumption levels and
intake patterns of stimulant drinks on the island.
6.2 Background
6.2.1 International studies
Quantitative analyses of the consumption patterns of
stimulant drinks have been previously carried out.
These include market research by Red Bull GmbH in
Austria and independent research studies in
Germany and Australia. Results from these analyses
suggest that the consumption of stimulant drinks is
prevalent among young people.
The German survey conducted in 1994, interviewed
1265 children and young adults between the ages of
10 and 19 years (129). Results indicated that 40% of
children aged 10 – 13 years had tasted stimulant
drinks, with 23% drinking on average one can (250
ml) of a stimulant drink per week. A survey
conducted in Austria in 1999 on behalf of Red Bull
GmbH, reported that 45% of respondents (15 - 50
years) had consumed one or more cans of Red Bull
during the previous week (3). Use of stimulant drinks
was higher in the younger age group (15 – 24 years)
compared with the older group (25 – 50 years).
In Australia, 381 children and young adults between
8 and 18 years were surveyed (130). Twenty seven
percent of males and 12% of females in the 8 – 13
year old category reported having tasted stimulant
drinks. While these studies did not report any
reasons for concern about the use of stimulant
drinks nor about their health or behavioural effects,
the Australian study noted that “healthcare
professionals should be aware that children as young
as 8 years consume these products”.
None of the above surveys investigated the
circumstances under which stimulant drinks were
actually consumed, or the maximum number of
stimulant drinks consumed on one occasion.
6.2.2 Consumption on the island of Ireland
The North/South Ireland Food Consumption Survey
conducted 1997–2000 is an analysis of the food
intake levels and consumption habits of the
population on the island of Ireland (14). The survey
used a 7-day estimated food record/diary in which all
foods and drinks consumed by the respondents
during the period were recorded.
Of 1379 individuals aged 18 – 64 years surveyed,
only 19 respondents reported consuming stimulant
drinks. Of those 19 subjects, 14 were male and 5
were female, and, with the exception of one male
subject, all were aged 19 – 31 years (14). The
median daily intake of the consumers was 0.29 cans
per day. There was a large range of intake. The 5th
percentile for consumers only was 0.04 cans per day,
whereas the 95th percentile was one can per day.
Although the weekly consumption figures appear
relatively modest, they mask the fact that some
subjects may have consumed large amounts over
relatively short periods of time.
6.3 Survey of the Consumption
patterns of Stimulant Drinks on 
the Island of Ireland
Against the above background, the Committee
considered it necessary to establish current
consumption patterns of stimulant drinks on the
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island of Ireland and particularly the consumption
behaviour of young children. The overall aim of the
survey commissioned by the FSPB was to establish
patterns of consumption of stimulant drinks in a
representative sample of the population of Ireland,
north and south, between the ages of 11 and 35
years.
The specific objectives of the research were to
provide information on the frequency and pattern of
use of stimulant drinks, the purpose of use, the
environment of use and the relationship of stimulant
drinks with alcohol.
An appropriate questionnaire was devised in
conjunction with Lansdowne Market Research
(Appendix I). A summary of the study is outlined
below and the full text of the qualitative study can
be obtained on the FSPB website at:
URL:http://www.safefoodonline.com/publications/pub
s.html.
6.3.1 Methodology
The survey was conducted as part of the Lansdowne
Market Research Omnibus Questionnaire, which is
run all year round on a fortnightly cycle. The
Omnibus Survey involves face-to-face interview of
1200 participants in the Republic of Ireland and
1100 in Northern Ireland, aged 15 – 64 years (16 –
64 years in Northern Ireland).
In order to obtain consumption data on stimulant
drinks among children, booster samples of 200
children in the Republic of Ireland (11 – 14 years)
and 200 children in Northern Ireland (11 –15 years)
were included. Participants in the Omnibus Survey
over the age of 35 years were not included in the
stimulant drinks survey.
Owing to self-imposed restrictions within the market
research industry, questions with regard to alcohol
and alcohol consumption were only asked of those
respondents over the age of 18 years. 
The fieldwork for the survey was conducted in 
July 2001.
6.3.2 Results
6.3.2.1 Overall demographics of survey
A total of 1260 individuals were surveyed regarding
their stimulant drink consumption and respondents
were equally distributed among social class and
gender. Details of the demographics of the survey
respondents are shown in Appendices II and III.
6.3.2.2 Frequency of drinking
The number of respondents who claimed to have
‘ever’* consumed or were ‘regular’* consumers of
stimulant drinks was quite a small number compared
with those who had ever or regularly consumed soft
or ‘fizzy’ drinks (Tables 6.1 and 6.2).
When asked, 51% of respondents in Northern Ireland
reported having ‘ever’ consumed stimulant drinks,
while 10% of respondents reported drinking stimulant
drinks on a regular basis. These figures were 37% and
11%, respectively, for the Republic of Ireland. 
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* ‘Ever’ drinking and ‘regular’ drinking was self-defined by respondents. ‘Ever’ drinking consumers were those who had ever
tasted or consumed stimulant drinks but did not consider themselves to be regular consumers. ‘Regular’ consumers described
individuals who consumed stimulant drinks frequently.
6.3.2.3 Prevalence of regular consumers of stimulant drinks by sex, age and social class
In Northern Ireland, 13% of males and 7% of females reported being regular consumers. In the Republic of Ireland,
these figures were 14% and 7% for males and females, respectively (Table 6.3).
There was no clear difference in the ages of consumers between Northern Ireland and the Republic of Ireland,
although consumers in the Republic of Ireland, tended to start younger and consumption was highest in the 19 – 24
years age group. In both jurisdictions there were no social class differences in consumption patterns (Table 6.3). 
6.3.2.4 When respondents started to drink stimulant drinks
In Northern Ireland, the majority of consumers of stimulant drinks (both ‘regular’ and ‘ever’ consumers) reported
having started to consume stimulant drinks approximately 1 - 2 years ago (i.e. 1999 – 2000), with less than 10%
having started to consume the drinks within the six months prior to the survey (Figures 6.1 and 6.2). Similarly, in
the Republic of Ireland most respondents reported starting to drink stimulant drinks one to two years ago,
although 13% of ‘regular’ drinkers reported having started within the month prior to the survey.
These results coincide with the introduction of stimulant drinks onto the market on the island of Ireland.
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Type of drink n % n %
Fizzy drinks 556 89 616 97
Energy drinks 425 68 502 79
Spirits 425 68 298 47
Flavoured drinks (bottle) 375 60 495 78
Coffee 350 56 381 60
Beer 338 54 324 51
Wine 250 40 279 44
Stimulant drinks 231 37 324 51
‘Ever’ Drinkers
Table 6.1 Whether respondents had ‘ever’ consumed a number of specified drinks
Republic of Ireland (n = 625) Northern Ireland (n = 635)
Type of drink n % n %
Fizzy drinks 431 69 476 75
Beer 238 38 152 24
Coffee 200 32 190 30
Energy drinks 181 29 146 23
Flavoured drinks (bottle) 169 27 216 34
Wine 88 14 83 13
Spirits 69 11 76 12
Stimulant drinks 69 11 63 10
‘Ever’ Drinkers
Table 6.2 Whether respondents ‘regularly’ consumed a number of specified drinks
Republic of Ireland (n = 625) Northern Ireland (n = 635)
6.3.2.5 Settings in which stimulant drinks were consumed
‘Pubs and clubs’ were the most important drinking locations for regular stimulant drink consumers in both
Northern Ireland and in the Republic of Ireland (Figure 6.3). When asked, 80% of 19 – 24 year olds who had
ever consumed stimulant drinks, had done so in a ‘pub or club’ setting. For respondents in the 11 – 18 year
old category, ‘with friends’ was the most likely setting in which they had ever consumed stimulant drinks.
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Northern Ireland 
n = 63 13 7 4 2 14 9 6 11 9 9
Republic of Ireland
n = 69 14 7 10 6 13 16 8 11 10 13
Sex Age (years) Social Class
Table 6.3 Distribution of regular consumers of stimulant drinks by age, sex and social class 
Male Female 11-12 13-14 15-18 19-24 25-35 ABC1 C2DE F
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Figure 6.2 When ‘regular’ consumers began drinking stimulant drinks
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Figure 6.1 When ‘ever’ consumers began drinking stimulant drinks
‘Before and after sport’ was also a common setting for the consumption of stimulant drinks, particularly with
males. However, surprisingly fewer respondents reported the use of stimulant drinks to stimulate them while
studying or working late, one of the ‘functional’ uses of the products promoted by the manufacturers (3).
When the drinking occasions of those respondents who reported ever consuming stimulant drinks were examined
in detail, it was established that there was no difference between male and female drinkers of stimulant drinks in
the contexts where they consumed the drinks. The only exceptions were sport in both Northern Ireland and the
Republic of Ireland, and work/school/college in the Republic of Ireland where more males than females reported
drinking stimulant drinks in these settings.
When the time of drinking of stimulant drinks was investigated, 75% and 65% of regular consumers reported
drinking the drinks most often between 5 pm and midnight in the Republic of Ireland and Northern Ireland,
respectively (Table 6.4). This result corresponds with a ‘pub or club’ setting for the consumption of stimulant
drinks. More respondents in Northern Ireland reported consuming stimulant drinks earlier in the day and this may
be associated with the higher use of stimulant drinks for their ‘functional’ properties within this population.
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Figure 6.3 Settings in which stimulant drinks were regularly consumed
7 am – midday 13 5
After midday – 5 pm 30 28
After 5 pm – midnight 65 75
After midnight – 7am 22 20
% Regular Drinkers
Table 6.4: Times at which regular drinkers consumed stimulant drinks
Time Northern Ireland (n = 63) Republic of Ireland (n = 69)
6.3.2.6 Consumption levels of stimulant drinks
The levels of consumption of stimulant drinks were examined in the survey. The weekly consumption was
approximately three cans (each can containing 250 ml) among consumers who had ever consumed stimulant
drinks (Figure 6.4). However, when data from the highest consumers (95th percentile) was examined, results
indicated that up to eight cans were consumed by some individuals in a week. Similarly, in a single session the
average number of stimulant drinks consumed was approximately three cans and among the highest consumers
rose to eight cans. This indicates that some individuals are consuming up to 640 mg caffeine in a single sitting. 
It should also be noted that in the younger age group (11 – 14 years), approximately two cans of stimulant drinks
were consumed in a single session (Figure 6.4). These points gives rise to concern regarding the acute effects of
stimulant drinks among adults and children.
Chapter 6 Studies of Consumption Levels and of Behaviour and Attitudes to Stimulant Drinks 
38
When the age ranges of stimulant drink consumers were examined, it was shown that all age ranges had
consumed stimulant drinks, however, the peak consumers fell into the 19 – 24 years age category (Figure 6.5).
This confirmed the findings of the qualitative research.
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Figure 6.4 The average number of cans of stimulant drinks consumed within each age group by ‘ever’
consumers (both north and south, n = 551)
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Figure 6.5 The average number of cans of stimulant drinks consumed by male and female ‘ever’
consumers (both north and south, n = 551)
There was little difference between the reported consumption levels of respondents in Northern Ireland and the
Republic of Ireland who had ever consumed stimulant drinks (Figure 6.5). Generally, females tended to consume less
stimulant drinks than males, and males in the Republic of Ireland consumed slightly more than their Northern Ireland
contemporaries.
6.3.2.7 Consumption of stimulant drinks with alcohol 
Stimulant drink consumption was strongly related to alcohol consumption in both the Republic of Ireland and
Northern Ireland (Table 6.5).
Among those who reported ever having consumed stimulant drinks, 84% of all respondents had consumed the
drinks with alcohol. Among regular drinkers, 56% of respondents consumed stimulant drinks with alcohol.
Equal numbers of males and females reported regularly consuming stimulant drinks on their own in the Republic of
Ireland, while in Northern Ireland, more males regularly consumed stimulant drinks on their own. In Northern Ireland,
more females than males regularly consumed stimulant drinks with vodka, while the opposite was the case in the
Republic (Table 6.6).
6.3.2.8 Attitudes and behaviour towards stimulant drinks
When respondents were asked to assign attributes and perceptions to stimulant drinks, results were broadly similar
in Northern Ireland and the Republic of Ireland (Table 6.7). However, there were differences between how regular
consumers and all respondents (including ‘ever’ and ‘regular’ consumers, and non-consumers of stimulant drinks)
categorised the drinks (Table 6.7).
A large number of all respondents to the survey considered stimulant drinks to be ‘unsafe’ in large quantities.
Attributes related to their ‘functional’ uses were considered as less important. Regular consumers, while also
acknowledging that the drinks were potentially ‘not safe’ in large quantities, considered their ‘popularity and
trendy status’ ahead of other attributes. Regular consumers were also more likely to categorise stimulant drinks
as a drink to ‘perk you up’ and ‘boost awareness and concentration’ than all respondents.
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With vodka 47 61 71 71
With other alcoholic drinks 2 2 18 7
Between alcoholic drinks 0 5 10 12
On their own 49 32 69 66
‘Regular’ (%) ‘Ever’ (%)
Table 6.5 Regular stimulant drink consumers (18 – 35 years) who reported consuming 
stimulant drinks with alcohol
NI (n = 49) RoI (n = 41) NI (n = 49) RoI (n = 41)
Northern Ireland (%) Republic of Ireland (%)
Table 6.6 Regular stimulant drink consumers (18 – 35 years) by sex, who reported drinking 
stimulant drinks with alcohol
With vodka 35 53 61 52
On their own 54 36 51 54
Male Female Male Female
Respondents were further asked about their attitudes towards stimulant drinks. Again results were similar in
Northern Ireland and the Republic of Ireland (Table 6.8). However, respondents in the Republic of Ireland gave
more consideration to the consumption of stimulant drinks with alcohol than respondents in Northern Ireland.
These results support the findings in section 6.3.2.7.
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People drink them to perk themselves up if they 
are tired 80 78 5 3
People drink them on big nights out 78 67 10 8
People drink them to perk themselves up if they 
have too much to drink 69 56 13 10
People drink them with alcohol to enable them to 
drink more in an evening 59 43 23 22
People can drink more if they drink a stimulant 
drink during the night 50 25 28 30
It is a drink for any occasion 41 41 42 28
Agree, % Disagree, %
Table 6.8 Agreement with statements (all consumers)
RoI NI RoI NI 
(n = 625) (n = 635) (n = 625) (n = 635)
Too much…not good 68 78
Fashionable/trendy drink 54 80
Drink mainly for youths 50 72
Becoming more popular 49 84
Mainly drunk with alcohol 47 73
Boosts concentration/awareness 42 69
Drink to perk you up 39 74
Good hangover cure 27 50
A sports drink 14 27
Drink for any occasion 10 20
Goes well with food 5 7
Attribute All respondents, % Regular stimulant 
(n = 1260) drinks consumers, 
(n = 132)
Figure 6.7 Attributes assigned by respondants
6.4 Summary
While 51% of respondents in Northern Ireland and 37% in the Republic of Ireland reported having ever consumed
stimulant drinks, only 10% in both jurisdictions considered themselves to be regular consumers. Analysis of the
results identified males between the ages of 19 and 24 as being the peak consumers.
The average number of cans consumed by ‘ever’ consumers in a single session was approximately three, while
three was also the average weekly consumption of ‘ever’ consumers. However, there are individuals who
consume up to eight cans in one session, and for these individuals, this exposure to very high caffeine
concentrations may pose a health risk, particularly if they suffer from an underlying medical condition. Little is
known about the consequences of exposure of these individuals to the high levels of taurine and
glucuronolactone to which they would also be subjected.
The Committee consider that the context in which stimulant drinks are consumed as central to any study of the
health effects of the drinks. When respondents were asked about the settings in which they consumed stimulant
drinks, ‘pubs and clubs’ were the venues of choice. Settings that are associated with the functional use of the
products, such as ‘studying’ and ‘working and driving’, were less significant.
On being asked in more detail regarding the consumption of stimulant drinks with alcohol, 84% of respondents
reported having ever consumed stimulant drinks with alcohol, while 56% reported consuming the drinks with
alcohol regularly.
While an equal number of females in Northern Ireland and the Republic of Ireland reported regularly consuming
stimulant drinks with alcohol (53%), more males in the Republic of Ireland were regular consumers of stimulant
drinks with alcohol compared with their contemporaries in Northern Ireland (61% and 35%, respectively). These
results confirm the qualitative results discussed in Chapter 5.
The attitudes and behaviour of respondents to stimulant drinks were addressed during the course of the consumer
survey. Attitudes are similar in the Republic of Ireland and Northern Ireland, although respondents in the latter
perceive a greater role for stimulant drinks with alcohol. 
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‘Stimulant drinks
are marketed with
claims such as
‘vitalises body and
mind’, ‘improves
psychological
performance’ and
‘the ultimate high’.
7.1 Introduction
Stimulant drinks are marketed with claims such as
‘vitalises body and mind’, ‘improves psychological
performance’ and ‘the ultimate high’. While no
specific health or nutritional claims are used in the
promotion of these products, concern has been
expressed with regard to some of the advertising
methods, marketing materials and sales promotion
techniques that are employed in the promotion of
stimulant drinks.
The Committee therefore considered that some of
the marketing approaches adopted by stimulant
drink companies should be examined. To this end, 
the Committee commissioned an assessment of the
marketing of stimulant drinks in Ireland, specifically:
• an analysis of the marketing material supporting
stimulant drinks in Ireland
• analysis of the distribution channels used by the
manufacturers of stimulant drinks
• the preparation of a report on the scope, scale,
content and inferred objectives of marketing
activity supporting stimulant drinks in Ireland.
This analysis of the market was carried out in
March – April of 2001. A summary of the analytical
results may be found in the following section, and
a copy of the full document is available for
consultation on the FSPB website:
URL:http://www.safefoodonline.com/publications/pubs.
html.
7.2 Market Review of Stimulant Drinks
on the Island of Ireland
7.2.1 The stimulant drink market on the 
island of Ireland
Analysis of the stimulant drink market on the island
of Ireland indicated that Red Bull is the market
leader with in excess of 87% share of the market
(3). Other products of any significance were V and
Shark. While Red Bull GmbH considers the range of
Lucozade energy drinks to be its most significant and
direct competitor (3), these products were not
considered in the analysis as they do not fit the
definition of stimulant drinks as developed by the
Committee in so far as they do not contain the
principal ingredients of stimulant drinks, i.e. caffeine,
taurine and glucuronolactone.
Due to the fact that Red Bull is the dominant player
in the stimulant drink market on the island of
Ireland, the marketing analysis focuses on the
marketing activity of Red Bull GmbH.
Market analysis indicates that the target group for
stimulant drinks is defined as adults aged between
16 and 39 years, with a core group of consumers
aged between 18 and 24 years. A consumption
survey carried out on behalf of Red Bull GmbH in July
2000 in the Republic of Ireland showed the highest
consumption levels amongst males aged 20 – 24
years and amongst D/E social class (3). On the basis
of this study, it is estimated that the average
consumption of stimulant drinks by consumers
within the core market (20 – 24 years) is 19 cans
(4.75 l) per month (3).
Sales per capita of Red Bull on the island of Ireland
are higher than in most of the other 52 countries in
which the stimulant drink is distributed. Examination
of the market suggests that the reason for this could
relate to the high levels of alcohol consumption, in
particular, the consumption of vodka, rather than its
penetration as a ‘functional energy drink’.
Results of the consumption survey conducted on
behalf of Red Bull GmbH indicate that stimulant
drinks are heavily used as mixers with vodka, with
25% of males and 32% of females claiming to
‘always’ drink Red Bull as a mixer. These results are
confirmed by the qualitative and quantitative
analyses discussed in Chapters 5 and 6.
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7.2.2 Distribution of Red Bull on the 
island of Ireland
In the survey conducted on behalf of Red Bull GmbH,
72% of participants claimed to drink Red Bull with
alcohol (3). A review of the distribution chain of
stimulant drinks indicated that 65% of Red Bull
distribution in the Republic of Ireland is through the
licensed trade, while in Northern Ireland, this channel
represents 45% of total sales. 
Red Bull GmbH denies the active promotion of its
product with alcohol (3) and it sees the long-term
success of the product being driven by its ‘functional’
properties, and not as a mixer with alcohol.
However, the marketing review suggests that it
continues to sell its product predominantly into the
licensed trade in the Republic of Ireland. Indeed their
marketing material is ambiguous in relation to
alcohol. In one of its brochures it states:
“Red Bull does not contain alcohol, but there is no
reason why it shouldn’t. Adding alcohol to Red Bull
does not change Red Bull’s properties”.
7.2.3 Marketing strategies
The analysis of the marketing activity of Red Bull
GmbH suggests that the company is concerned with
the promotion of its product as a ‘functional’ drink.
There are three core strategies employed by Red Bull
GmbH in all markets, namely advertising, sampling
and sponsorship.
7.2.3.1 Advertising
Red Bull GmbH uses television, radio and cinema, 
but not print or outdoor advertising, although point-
of-sale literature is available. Television and cinema
advertising is cartoon based, and is used in all markets
where Red Bull is distributed throughout the world.
7.2.3.2 Sampling
Examination of the market indicates that Red Bull
GmbH strongly support the use of product sampling
in the promotion of the drink. This is based on the
premise that if a potential consumer experiences the
product in the ‘right’ situation (i.e. when they need
energy), they will become a repeat purchaser. As of
April 2001, there were ten sampling teams in the
Republic of Ireland and four in Northern Ireland.
These teams target individuals such as taxi drivers,
nurses and late night workers.
In addition to the sampling teams, Red Bull GmbH
employs student brand managers. In April 2001,
there were six student brand managers on campuses
in the Republic of Ireland. According to Red Bull
GmbH, the role of the student brand manager is to
represent the brand on campus, to educate students
about the benefits of the product and to encourage
trial and future purchase.
‘Fact brochures’ are available to support the
sampling teams and the student brand manager. Red
Bull GmbH produces these brochures with the
objective to ‘communicate’ the functional aspects 
of its product. The fact brochures include:
• “Your Personal Trainer Comes in a Can”
aimed at sports/active people
• “Wakey Wakey Alive Very Alive”
aimed at drivers.
However, the marketing review observed that in
addition to the above, some of the verbal messages
being given by the sampling staff may be over-
claiming for the product. (Claims such as “It breaks
down things that are clogged in your body and
flushes them out. It’s like an inner cleanser…and…
protects against gall bladder disease and facial
twitches …and can also help epilepsy.”)
7.2.3.3 Sponsorship
Sport is the main focus of the sponsorship
programme and the emphasis is on emerging and
established extreme sports. Red Bull is seen to be
associated with ‘extreme’ sports in all its markets.
Analysis indicates that the strategy adopted is
designed to support both the ‘functionality’
positioning of the product and the ‘personality’ 
of the brand.
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7.3 Regulation of the advertising 
of stimulant drinks
7.3.1 Advertising regulation in the 
Republic of Ireland
In the Republic of Ireland, the Advertising Standards
Authority for Ireland (ASAI) is a self-regulatory body
established by the advertising industry to ensure that
advertisers comply with the requirements of the
Code of Advertising Standards and of Sales
Promotion Practices as published by the ASAI. While
there are no specific provisions or references in the
Codes with regard to the advertising of soft drinks,
including stimulant drinks, all products are assessed
in light of an advertisement’s probable effect given
the context. In this regard, particular attention is paid
to the characteristics of the likely audience, the
media used, the location and context of the
advertisement and the nature of the advertised
product (131).
There have been a number of complaints lodged
with the ASAI regarding the promotional campaigns
used by Red Bull GmbH. One complaint concerned a
television advertisement for Red Bull featuring
cartoon characters. The complainant suggested that
the product was a high caffeine drink that the
advertiser, in its own product information, stated was
unsuitable for children. The complainant believed
that this advertisement posed unnecessary risks to
children’s health, particularly in the absence of
legislation that would restrict access to the product.
The complaint was not upheld by the ASAI as the
advertisements used were shown after the 9 pm
water shed and the cartoon characters used were
found to be neither specifically designed for children
nor familiar to children in general.
Another complaint was received by the ASAI
regarding the claims made by Red Bull GmbH in a
booklet widely available throughout the country. The
claims include:
• “Red Bull keeps your eyes wide open and on
the road”
• “You’ve got better things to do than sleep”
• “Red Bull does not contain alcohol, but there is
no reason why it shouldn’t. Adding alcohol to Red
Bull does not change Red Bull’s properties”.
The complainant objected to the booklet on the
basis that the claims were offensive and gave
exceptionally irresponsible advice in a situation of
general concern about road safety. To date no
decision has been taken on this complaint although
such promotional material, known as point-of-sale,
falls outside the remit of the ASAI.
7.3.2 Advertising regulation in the UK
In the UK, the Advertising Standards Authority (ASA)
performs a similar role to that of the ASAI in Ireland.
In 1997, an objection to advertisements for Red Bull
was lodged. In its advertising, Red Bull GmbH claimed
that its product:
• “improves concentration”
• “improves reaction time”
• “improves endurance”
The complainant challenged whether the advertisers
could substantiate these claims. 
In January 2001, the ASA found in favour of the
complainant on the basis that at the time of the
original complaint, there was insufficient scientific
evidence to support the claims made by Red Bull
GmbH (132). While Red Bull GmbH had subsequently
provided scientific evidence to support its claims, the
ASA noted that this evidence related to a caffeine
concentration much higher than that present in a
single can (250 ml) of Red Bull as implicated in its
advertising. The ASA recommended that in the
future Red Bull GmbH should submit all
advertisements to the Committee of Advertising
Practice for prior approval.
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7.4 Summary
The marketing review indicates that sales of
stimulant drinks on the island of Ireland have peaked
and that current levels of sales figures are now
running at approximately 20% below the levels of
2000. Recent trends suggest that the use of
stimulant drinks such as Red Bull as a mixer with
alcohol is beginning to be replaced by other more
‘trendy’ products on the market (e.g. Bacardi Breezer,
Smirnoff Ice). However, stimulant drinks still have a
strong and loyal consumer base and there are
indications that, in spite of the manufacturers’
claims, large quantities continue to be consumed
with alcohol.
The analysis of the marketing activity of stimulant
drinks highlights two main areas of concern:
• some of the verbal messages being given by the
sampling staff may be over-claiming for the
product. (Claims such as “It breaks down things
that are clogged in your body and flushes them out.
It’s like an inner cleanser…and… protects against
gall bladder disease and facial twitches …and can
also help epilepsy.”)
• some of the promotional brochures encourage
people to drink Red Bull rather than to sleep. Even
allowing for an element of permissible advertising
licence, it is not clear whether the brochures are
intended to be taken literally or not. However, as
written material they have the capacity to be taken
to mean exactly what they say, and these
inferences could be injurious to health.
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‘Market analysis
indicates that the
target group for
stimulant drinks is
defined as adults
aged between 16
and 39 years, with
a core group of
consumers aged
between 18 and
24 years.’
‘It is recommended
that stimulant drinks 
not be consumed in
association with
sport and exercise as 
a thirst quencher.’
8.1 Introduction
In reviewing the adverse health effects of stimulant
drinks, the Committee was constrained by the limited
amount of comprehensive information, risk
assessment data and peer reviewed scientific research
in this area. In light of this limited information and in
order to protect public health, the Committee has
adopted a precautionary approach to its review and
makes the following recommendations.
8.2 Labelling
There is currently no specific legislation governing
stimulant drinks within the EU although, owing to
domestic legislation, stimulant drinks are not sold in
a number of countries.
In February 2002, EU Member States agreed
changes to the labelling regulations. These changes
will require drinks with caffeine contents greater
than 150 mg per l to be labelled ‘high caffeine
content’ and the amount of caffeine present must
be given. The new rules must come into effect by
July 1st 2004.
The Committee welcomes the new ruling
on caffeine labelling in the EU, i.e. that
drink products with caffeine contents
greater than 150 mg per l should be
labelled ‘high caffeine content’ and that
the amount of caffeine present in the
product be given. This ruling be
implemented as soon as is practicable.
The Committee also recommends that
stimulant drinks should be labelled with an
indication that they are unsuitable for
children (under 16 years), pregnant women
and individuals sensitive to caffeine.
8.3 Groups for Special Consideration
The Committee reviewed the current knowledge
with regard to the individual ingredients of stimulant
drinks. The Committee gave close consideration to
the use of stimulant drinks by individuals who may
be at increased risk due to the high caffeine nature
of these products, specifically pregnant women,
caffeine-sensitive individuals and children.
In the context of advice to pregnant women
to limit caffeine intake owing to the possible
adverse effects of high caffeine intake on
pregnancy outcome, stimulant drinks should
be classified with other beverages of high
caffeine content.
Consumption of stimulant drinks by children
under 16 years should be discouraged on the
basis of possible transient behavioural effects
of high caffeine intake, such as increased
arousal, irritability, nervousness or anxiety.
8.4 Circumstances under which
Stimulant Drinks are Consumed
The use of stimulant drinks during sport and exercise
was a concern for the Committee, particularly as it
was under such circumstances that the present
review was commissioned.
It is recommended that stimulant drinks not
be consumed in association with sport and
exercise as a thirst quencher, and that the
products should carry a clear statement on the
label that they are unsuitable rehydration
agents for use in sport and during exercise.
The effect of stimulant drinks in combination with
alcohol and other stimulants was also reviewed.
Given the limited information available, the main
areas of concern regarding stimulant drinks and 
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alcohol consumption are the dehydration effects and
the increased consumption of alcohol. Results of
qualitative and quantitative research indicate that
stimulant drinks are commonly consumed with
alcohol, particularly vodka. 
Consumers should be advised that caution
be exercised in the consumption of
stimulant drinks with alcohol and the
products should carry a clear statement on
the label to this effect.
8.5 Marketing
Market analysis reveals that the sale and consumption
of stimulant drinks on the island of Ireland has declined
in the past two years. However, a core market group
remains, specifically male aged 19 – 24 years.
The Committee has a number of concerns about the
marketing and promotion of stimulant drinks
including:
• misleading claims
• suggestion that stimulant drinks reduce the
requirement for sleep
• lack of recommended upper consumption limits
• ambiguous information on the consumption of
stimulant drinks with alcohol
• promotion of stimulant drinks consumption in
association with sport. 
It is recommended that the industry
regulators and relevant authorities address
such practices.
8.6 Further Research
The Committee recognises that in order to undertake
a full risk assessment of the ingredients of stimulant
drinks and their interactions, extensive research
would need to be conducted. Such research would
require toxicological investigations that would best
be carried out at an international level and concerted
international research should be undertaken.
It is therefore recommended that further
research be carried out to:
• monitor patterns of stimulant drink
consumption
• establish an upper safe level for daily
intake of glucuronolactone and taurine 
in humans
• investigate possible adverse effects of
interactions between stimulant drink
ingredients such as caffeine and taurine,
between such ingredients and alcohol, 
and under conditions of exercise and
consequent dehydration.
Chapter 8 Recommendations
50
Stimulant Drink Survey Questionnaire
Ask all aged 15-35 only
Showcard ‘1’
Q.1 Which of the following types of drink have you ever drunk?
Q.2 Which of the following types of drink do you drink regularly?
Q.3 Which of the following types of drink do you drink most often?
Single Code Only
Ask all ever drinking stimulant drinks (Code 3 at Q.1) Others go to Q.13.
Showcard ‘2’
Q.4 How long ago did you start to drink stimulant drinks like Red Bull, Red Lion or V?
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Fizzy drinks (e.g. Coke/7UP/Fanta etc) 1 1 1
Energy drinks (e.g. Lucozade Energy/Finches Fuel/Gatorade) 2 2 2
Stimulant Drinks (e.g. Red Bull, V, Red Lion, Shark etc) 3 3 3
Bottled/Flavoured Water 4 4 4
Beer 5 5 5
Wine 6 6 6
Spirits (e.g. Vodka, Whiskey) 7 7 7
Coffee 8 8 8
Q.1 Q.2 Q.3 
Ever Regularly Most Often 
1 month or less 1
2-3 months ago 2
4-6 months ago 3
6 months to 1 year ago 4
Between 1 and 2 years ago 5
More than 2 years ago 6
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Showcard ‘3’
Q.5 On which, if any, of these occasions do you ever drink Stimulant Drinks such as Red Bull, Red Lion or V?
Q.6 On which, if any, of these occasions do you regularly drink Stimulant Drinks such as Red Bull, Red Lion,
or V?
Q.7 On which, if any, of these occasions do you drink Stimulant Drinks such as Red Bull, Red Lion or V
most often?
Showcard ‘4’
Q.8a At which of these times do you ever drink stimulant drinks such as Red Bull, Red Lion or V?
Q.8b At which of these times do you regularly drink stimulant drinks such as Red Bull, Red Lion or V?
Q.8c At which of these times / occasions do you drink stimulant drinks such as Red Bull, Red Lion or V
most often?
Q.9 When drinking stimulant drinks (On most often occasion Q7), how many cans on average do you drink in
one session?
Q.10 How many cans of stimulant drinks would you drink in an average week?
Q.11 What is the most number of cans you have drunk in one session?
At home 1 1 1
In pubs/clubs 2 2 2
When out with friends 3 3 3
With Meals 4 4 4
While studying/working late 5 5 5
At work/school/college 6 6 6
Before sport 7 7 7
After sport 8 8 8
When driving 9 9 9
Q.5 Q.6 Q.7 
Ever Regularly Most Often 
7am – mid-day 1 1 1
After mid-day to 5pm 2 2 2
After 5pm to midnight 3 3 3
After midnight to 7am 4 4 4
Q.8a Q.8b Q.8c
Ever Regularly Most Often 
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Showcard ‘5’
Q.12a When drinking stimulant drinks like Red Bull, please tell me which of the following ever applies to you.
Q.12b Which applies most often
Ask all
Showcard ‘6’
Q.13 Please tell me which, if any, of the following statements apply to these types of soft drink, you
may mention as many or as few as you like.
R
I drink it on its own without mixing 1 1
I drink it with Vodka 2 2
I drink it with Gin 3 3
I drink it with Rum 4 4
I drink it with other alcoholic drinks 5 5
I drink it in between alcoholic drinks 6 6
Ever Most Often 
It’s a drink that boosts concentration and alertness 1 1 1
It’s a drink for any occasion 2 2 2
It's a drink to perk you up 3 3 3
It's a sports drink 4 4 4
It's a drink mainly drunk with alcohol 5 5 5
It’s a drink mainly for drinking in pubs 6 6 6
It's a drink that goes well with food 7 7 7
It’s a good hangover cure 8 8 8
Too much of it would not be good for you 9 9 9
It’s a drink that is becoming more popular 1 1 1
It’s a fashionable/trendy drink 2 2 2
Read out Fizzy Drinks Energy Stimulant 
➳ (e.g Coke/ Drinks Drinks
7Up)
Showcard ‘7’
Q.14 I am now going to read out some comments that people have made about stimulant drinks like Red Bull,
Red Lion, V etc. Please tell me to what extent you agree or disagree with each of these statements?
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People drink them with alcohol
to enable them to drink more in
an evening 1 2 3 4 5 6
People drink them on a big
night out 1 2 3 4 5 6
People drink then to perk
themselves up if they’ve had too
much to drink 1 2 3 4 5 6
People drink them to perk
themselves if they are tired 1 2 3 4 5 6
People can drink more if they
drink Red Bull during the night 1 2 3 4 5 6
It is a drink for any occasion 1 2 3 4 5 6
Read Out Agree Agree Neither Agree Disagree Disagree Don’t  
Strongly nor Disagree Strongly Know
Appendix III
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Appendix II
Total (n) 625 313 312 51 54 141 131 248 261 310 54
Sex
Male (n) 313 313 30 25 67 72 119 134 154 25
Male (%) 50 100 59 46 48 55 48 51 50 46
Female (n) 312 312 21 29 74 59 129 127 156 29
Female (%) 50 100 41 54 52 45 52 49 50 54
Sex Age Social Class
Table I Demographics of respondents in the Republic of Ireland
Total Male Female 11-12 13-14 15-18 19-24 25-35 ABC1 C2DE F
Total (n) 635 306 329 49 60 109 147 270 259 151 225
Sex
Male (n) 306 306 22 33 55 76 120 125 76 105
Male (%) 48 100 45 55 50 52 44 48 50 47
Female (n) 329 329 27 27 54 71 150 134 75 120
Female (%) 52 100 55 45 50 48 56 52 50 53
Sex Age Social Class
Table II Demographics of respondents in Northern Ireland
Total Male Female 11-12 13-14 15-18 19-24 25-35 ABC1 C2 DE
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Alkaloids: Naturally occurring nitrogen containing
compounds that have pharmacological actions in
man and other animals.
Ambulatory Blood Pressure: Normal blood
pressure when standing.
Analgesic: A substance used in medicine to 
relive pain.
Aortic Wave Form: A measure of pressure in 
the heart shown diagrammatically as a wave.
Arrhythmia: An abnormal heart rhythm.
Arterial Stiffness: The stiffening of the arteries
which is thought to contribute to the increased
incidence of cardiovascular disease with age.
Blood Pressure: The pressure of the blood within
the arteries. It is produced primarily by the
contraction of the heart muscle. Two numbers 
record its measurement. The first (systolic pressure) 
is measured after the heart contracts and is the
highest. The second (diastolic pressure) is measured
before the heart contracts and is the lowest.
Cardio Vascular Disease (CVD): A disease relating
to, or involving the heart, and blood vessels. 
Cardio Vascular System: The circulatory system
comprising the heart and blood vessels. The system
carries nutrients and oxygen to the tissues of the
body and removes carbon dioxide and other wastes
from them.
Congenital Malformations: A physical defect
present in a baby at birth, irrespective of whether
the defect is caused by a genetic factor or by
prenatal events that are not genetic.
Diuresis: Increased formation and excretion of urine.
Dopamine: Neurotransmitter found in the brain that
is a precursor of adrenaline and noradrenaline.
Dopaminergic: Dopamine-induced effects.
Electrolyte Loss: The loss of salts from the body,
usually sodium and potassium. 
Ephedrine: A substance that stimulates contraction
of the smooth muscle of the capillaries and arteries
and causes a secondary release of noradrenaline. 
It causes increases in blood pressure and it is used
when blood pressure drops e.g. during anesthesia.
Epidemiological Studies: The assessing of specific
characteristics of large groups of people in order 
to identify which factors may influence the
development of diseases.
Epinephrine: A hormone secreted by the adrenal
glands, especially in times of stress or in response to
fright or shock. Its main actions are to increase blood
pressure and mobilize tissue reserves of glucose.
Ergogenic Aids: Compounds that have been
promoted as helping to improve performance in 
a variety of ways such as altering body composition 
or by enhancing energy efficiency, energy control 
or energy production.
Glycaemic Index: The increase in blood glucose
after a test dose of a carbohydrate, relative to that 
in response to an equivalent amount of glucose. 
Half Life: The period over which the concentration
of a specified chemical or drug takes to fall to half its
original concentration in the specified fluid or blood. 
Heart Disease: Group of symptoms arising from the
failure of the coronary arteries to supply sufficient
blood to heart muscles.
Homeostasis: A tendency of biological systems to
maintain stability while continually adjusting to
conditions which are optional for survival.
Hypercholesterolaemic: Abnormally high
concentrations of cholesterol in the blood. Normal
total plasma cholesterol is below 5.2mmol/l. Raised
levels of cholesterol are generally considered to be a
sign of high risk of atherosclerosis and heart disease.
Hypertonic: A solution more concentrated than
body fluids.
Intraperitoneal: Within the peritoneal cavity. 
The area that contains the abdominal organs. 
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Isotonic Drinks: Drinks with the same osmotic
pressure as body fluids.
Meta Analysis: A review of the results of past
studies done on a particular subject which draws
conclusions based on this combined analysis.
Mitral Valve: A valve within the heart found
between the upper and lower cambers of the left
side. This valve opens and closes as blood flows
through the heart.
Mitral Valve Prolapse: Drooping down or
abnormal bulging of the mitral valve during the
contraction of the heart.
Myocardial Infarction: The changes that occur to
the heart muscles due to sudden (acute) deprivation
of circulating blood.
Natriuresis: The excretion of sodium salts in the urine.
Ossification: The process of creating bone, that is 
i.e. transforming cartilage (or fibrous tissue) into bone.
Placebo: An inert, harmless treatment (such as a
sugar pill) given to the control group so that both
control and experimental groups receive what
appears to be identical treatment during the study.
Platelet Aggregation: The clumping together of
the irregular, disc-shaped element in the blood that
assists in blood clotting. 
Pre-Term Birth: Birth before 37 weeks of gestation.
Psychoactive: Substances that alter mood, cognition
or behaviour.
Psychomotor: Pertaining to motor effects of
cerebral or psychic activity. Movement produced 
by action of the mind or will.
Pulse Wave Velocity: Pulse wave describes the
waveform of the pressure formed by blood as it runs
through the blood vessels. It varies because of the
contraction of the heart, reaching a peak equivalent
to systolic measurements of blood pressure and a
trough equivalent to the diastolic measurement of
blood pressure. Pulse wave velocity refers to the
speed of the pulse wave and is thought to be a
reliable index of the assessment of the degree of
atherosclerosis.
Sudden Adult Death Syndrome: The term given
to the sudden death generally of young adults 
from lesser-known heart conditions. Usually,
atherosclerosis of the heart is not the cause. More
often these young victims have a thickened muscle
(hypertrophic cariomyopathy) without accompanying
high blood pressure.
Tachycardia: Rapid heartbeat, as occurs after
exercise. It may also occur without undue exertion 
as a result of anxiety.
Vasoconstrictor: Constriction of the blood vessels.
Vasodilatory: Dilation of the blood vessels caused
by a rise in body temperature.
Xenobioctics: Substances foreign to the body,
including drugs and some food additives. 
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